atorvastatin has been researched along with Atherogenesis in 344 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 79 (22.97) | 29.6817 |
| 2010's | 213 (61.92) | 24.3611 |
| 2020's | 52 (15.12) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Liang, Z; Nie, M; Yan, Y; Zhang, X; Zhao, Q | 2 |
| Broncel, M; Gorzelak-Pabiś, P; Niedzielski, M; Woźniak, E | 1 |
| Angermann, C; Armitage, J; Baigent, C; Barter, P; Baxter, A; Blaustein, R; Bowman, L; Braunwald, E; Brenner, S; Cannon, C; Chen, F; Chen, Y; Chen, Z; Collins, R; Dayanandan, R; DeLucca, P; Ertl, G; Fabbri, G; Fajardo-Moser, M; Goodenough, R; Goto, S; Gray, A; Hao, D; Haynes, R; Herrington, W; Hill, M; Hopewell, JC; Knott, C; Landray, M; Lay, M; Liu, J; Lucci, D; Macdonnell, S; Maggioni, A; Mihaylova, B; Mitchel, Y; Mosegaard, S; Murphy, K; Sammons, E; Stevens, W; Tobert, J; Valdes-Marquez, E; Wallendszus, K; Wanner, C; Wincott, E; Wiviott, S; Wuhan, B; Zhang, H | 1 |
| Borghi, C; Levy, BI | 1 |
| Cui, D; Gao, L; Liu, J; Liu, L; Qi, Y; Tan, H; Wang, Z | 1 |
| Alaylioglu, M; Dogan, AS; Dursun, E; Gezen-Ak, D; Onal, B; Ugurlucan, M; Yenmis, G | 1 |
| Ali, NA; Gali, F; Hadi, N; Saud, A | 1 |
| Antohe, F; Boteanu, RM; Cerveanu-Hogas, A; Hansen, R; Ivan, L; Suica, VI; Uyy, E | 1 |
| Cinque, G; Dowling, LM; Njoroge, W; Sulé-Suso, J; Xie, B; Yang, Y | 1 |
| Ren, Y; Wang, L; Yao, H; Zhao, X | 1 |
| Gao, T; Jiang, L; Li, F; Li, S; Liu, M; Shi, B | 1 |
| Amarenco, P; Bath, PM; Chen, W; Gao, Y; Han, S; Jing, J; Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, T; Wang, Y; Yang, Y; Zhao, X | 1 |
| Broncel, M; Gorzelak-Pabiś, P; Niedzielski, M; Woźniak, A; Woźniak, E | 1 |
| Li, Y; Liu, X; Mu, Y; Peng, W; Qiu, Q; Zhang, D; Zhang, Y | 1 |
| Qiu, Y; Yang, G | 1 |
| Li, W; Liang, J; Liu, H; Liu, J; Pi, X; Qu, L; Wang, T; Zou, W | 1 |
| Huang, J; Shi, R; Wang, X; You, B; Zhang, G; Zhao, M; Zhou, M | 1 |
| Biswal, J; Chandra, A; Dash, R; Goel, VK; Mohapatra, S; Prusty, SK; Sharma, T; Yadav, M | 1 |
| Chen, C; Jin, S; Liu, S; Yao, H; Zhang, L; Zhao, Y; Zheng, Z | 1 |
| Al Zoubi, S; Al-Hawamdeh, M; Alrashdan, R; Ayyad, D; Gharaibeh, L; Sartawi, H | 1 |
| Adeneye, AA; Afolabi, SO; Ajayi, AM; Folahan, JT; Njan, AA; Okoye, II; Olorundare, OE; Oyewopo, AO; Soyemi, SS | 1 |
| Ali, N; Gali, F; Hadi, NR; Qassam, H; Saud, A | 1 |
| Li, MR; Li, NS; Lu, LQ; Luo, XJ; Peng, J; Peng, JY; Tang, LJ | 1 |
| Fu, X; Li, F; Li, H; Liang, X; Liu, K; Yang, J; Zhang, A; Zhu, N | 1 |
| Cassola, N; Clezar, CN; Flumignan, CD; Flumignan, RL; Nakano, LC; Trevisani, VF | 1 |
| Aman Nasution, S; Estiasari, R; Jasirwan, COM; Purnamasari, D; Rusdi, L; Shinta Noviar, M; Syahrir Azizi, M; Wulandari, EAT; Yunihastuti, E | 1 |
| An, N; Chen, L; Chen, Z; Feng, L; Huang, Z; Li, Q; Wang, R; Wu, W; Yan, Y; Yang, X; Zhang, W; Zhong, M; Zhu, Y | 1 |
| Huang, H; Lu, C; Luo, T; Wu, Q; Xiong, S; Xiong, Y; Zeng, J; Zhang, Z | 1 |
| Arain, HA; Carsons, SE; DeLeon, J; Kasselman, LJ; Petri, M; Reiss, AB; Renna, HA; Voloshyna, I; Zhen, J | 1 |
| Hale, G; Lyver, E; Stein, B; Ward, T | 1 |
| Du, W; Han, B; Hou, J; Hou, S; Huang, X; Liu, D; Liu, Q; Lv, H; Nie, H; Sun, Y; Wang, G; Wang, X; Yang, M; Yu, B; Zhang, L; Zhang, R | 1 |
| Civeira, F; Fuentes, F; Laclaustra, M; Marco-Benedi, V; Ortega, E; Perez-Calahorra, S; Pinto, X; Plana, N; Sanchez-Hernandez, RM | 1 |
| Bai, HL; Chen, F; Ding, L; He, X; Hu, YW; Kang, CM; Li, LM; Li, XH; Liu, XH; Lu, ZF; Wu, CM; Wu, LM; Wu, Q; Wu, SG; Xu, YJ; Zhang, RY; Zheng, L | 1 |
| An, L; Jia, Z; Lu, Y; Teng, X; Wang, J; Wang, S; Xu, C | 1 |
| Jia, G; Liu, X; Sun, R; Zhang, W; Zhao, M | 1 |
| Chakrapani, LN; Kalaiselvi, P; Singh, A; Srinivasan, AK | 1 |
| Hurt-Camejo, E | 1 |
| Assali, M; Berus, JM; Ceneri, N; Choudhary, G; Christensen, JL; Dong, W; Healy, A; Lee, C; Mantsounga, C; Morrison, AR; Neverson, J; Nilson, R; Watts, JP; Wu, WC | 1 |
| Bai, Y; Deng, J; Hao, H; Huang, Y; Li, S; Meng, L; Nan, D; Peng, Q; Shen, Z; Yu, W; Yu, Z | 1 |
| Chen, GL; Li, GY; Lyu, L; Na, S; Qi, Q; Zhang, WZ | 1 |
| Fang, S; Fu, Y; Gu, X; Li, C; Liu, S; Maegdefessel, L; Peng, X; Piao, M; Qian, F; Qin, Z; Qu, W; Sun, C; Sun, Q; Tian, J; Wang, C; Wang, X; Xi, X; Yu, B; Zhang, M; Zhong, S | 1 |
| Gao, C; Huang, Q; Kwong, CHT; Lee, SMY; Liu, C; Wan, JB; Wang, R; Yue, L | 1 |
| Fu, G; Li, Y; Luan, Y; Lv, Q; Xu, T; Zhang, W; Zhao, L | 1 |
| Arefieva, TI; Filatova, AY; Masenko, VP; Noeva, EA; Osokina, AK; Potekhina, AV; Provatorov, SI; Romasov, IV; Samko, AN; Shchinova, AM; Shlevkova, GV; Zharova, EA | 1 |
| Bender, K; Bonaterra, GA; Kelber, O; Kinscherf, R; Metz, J; Metz, S; Schwarzbach, H; Weiser, D; Wilhelm, B | 1 |
| Ahn, S; Ha, J; Min, SK; Oh, GT; Song, EJ | 1 |
| Du, Y; Feng, J; Ye, Q; Zha, K; Zheng, S | 1 |
| Aslan, G; İlhan, N; Sahin, K; Sahna, E; Sezgin, D; Tuzcu, M | 1 |
| Han, Z; Li, J; Wang, Y | 1 |
| Cao, X; Chen, Y; Huang, X; Li, Y; Wu, L; Xiao, H; Zhou, X | 1 |
| Bode, C; Boettler, T; Dederichs, TS; Dufner, B; Ehlert, CA; Härdtner, C; Heidt, T; Hilgendorf, I; Ho-Tin-Noé, B; Hoppe, N; Jander, A; Kaeser, R; Kohl, P; Kornemann, J; Krebs, K; Madl, J; Pieterman, EJ; Princen, HMG; Rauterberg, S; Robbins, CS; Sharipova, D; Stachon, P; Starz, C; Swirski, FK; von Zur Mühlen, C; Willecke, F; Wolf, D; Zirlik, A; Zou, J | 1 |
| Aguilar, GS; Chai, Z; Lakshman, S; Lamon-Fava, S; Lichtenstein, AH; Matthan, NR; Turner, JR; Urban, JF; Walker, ME; Ye, S | 1 |
| Chai, Z; Chen, C; Dawson, H; Lakshman, S; Lamon-Fava, S; Lichtenstein, AH; Matthan, NR; Solano-Aguilar, G; Turner, JR; Urban, JF; Walker, ME; Ye, S | 1 |
| Hoogeveen, RM; Kaiser, Y; Kroon, J; Moens, SJB; Stroes, ESG; Verberne, HJ; Verweij, SL; Vogt, L | 1 |
| Ha, J; Kang, M; Kang, SM; Lee, B; Lee, CJ; Lee, SH; Oh, J; Park, JM; Park, S | 1 |
| Liu, H; Lv, J; Su, G; Su, H; Sun, G; Tang, Y; Zhang, W | 1 |
| Chan, JYW; Cheung, DWS; Fung, KP; Ko, ECH; Koon, JCM; Lau, VKM; Wat, ECL; Waye, MMY; Wong, PH; Yau, KC | 1 |
| Abdel-Gabbar, M; Anwar, S; El-Zanaty, AM; Esmail, M; Kandeil, M | 1 |
| Ballantyne, CM; Beacham, LA; Miller, DL; Nicholls, SJ; Nissen, SE; Ray, KK; Riesmeyer, JS; Ruotolo, G | 1 |
| Alaupovic, P; Bagdade, J; Barter, P; Quiroga, C | 1 |
| Hellberg, S; Jauhiainen, M; Knuuti, J; Liljenbäck, H; Metso, J; Nuutila, P; Roivainen, A; Saraste, A; Saukko, P; Savisto, N; Silvola, JMU; Sippola, S; Ståhle, M; Virta, J; Ylä-Herttuala, S | 1 |
| J B, VK; Madhusudhan, B; Ramakrishna, S | 1 |
| Fang, ZF; Guo, Y; Li, XP; Long, JK; Luo, F; Peng, DQ; Ruan, GY; Xia, Q; Zhao, SP; Zheng, XL | 1 |
| Kokilambigai, KS; Lakshmi, KS; Seetharaman, R | 1 |
| Cannon, CP; Khan, I; Klimchak, AC; Reynolds, MR; Sanchez, RJ; Sasiela, WJ | 1 |
| El-Barbari, AA; El-Tamalawy, MM; Hassan, TM; Ibrahim, OM | 1 |
| Aibibula, A; Shabiti, A; Tuerxun, A; Wufuer, H | 1 |
| Lv, YZ; Wang, HM; Wang, ZZ; Xiao, W; Zhou, JM | 1 |
| Ferreira, J; Giugliano, RP; Huber, K; Keech, A; Lewis, BS; Murphy, SA; Pedersen, TR; Pineda, AL; Sabatine, MS; Sever, PS; Somaratne, R; Tokgozoglu, SL | 1 |
| Berbée, JFP; Boon, MR; Gart, E; Groen, AK; Hoeke, G; Klop, HG; Mol, IM; Pieterman, EH; Princen, HMG; Rensen, PCN; van Dam, AD; van den Berg, SM; Wang, Y | 1 |
| Ahn, Y; Cho, BR; Hur, SH; Jang, Y; Jeong, JO; Kim, DI; Lee, BK; Lee, CJ; Lee, SH; Oh, J; Rhee, MY; Woo, JT | 1 |
| Liu, C; Liu, Z; Zhang, Y; Zhou, M | 1 |
| Duan, RS; Li, H; Li, YK; Liu, RT; Yang, CL; Yue, LT; Zhang, M; Zhang, N; Zhang, P | 1 |
| Guo, M; Liu, C; Shao, B; Tang, Y; Wang, Y; Wu, H | 1 |
| Baydoun, D; Ibdah, R; Ibrahim, K; Mayyas, F | 1 |
| Al Awadhi, M; Al Mahmeed, W; Al Tamimi, O; Al-Hinai, AT; Al-Mahruqi, F; Al-Rasadi, K; Al-Zakwani, I; Arafah, M; Santos, RD; Shehab, A | 1 |
| Ballantyne, CM; Baum, SJ; Davidson, MH; Koren, A; Langslet, G; Mandel, J; McCullough, PA; Sanganalmath, SK; Shah, PK | 1 |
| Chen, XH; Deng, YQ; Tan, Y; Wu, FL; Wu, XM; Yang, DJ; Zhang, XW; Zhou, F | 1 |
| Filardi, PP; Maggioni, AP | 1 |
| Beshah, E; Goldbaum, A; Jang, S; Lakshman, S; Lamon-Fava, S; Lichtenstein, AH; Matthan, NR; Meng, H; Molokin, A; Solano-Aguilar, G; Stanley, J; Urban, JF; Walker, ME; Xie, Y | 1 |
| Barter, PJ; Karlson, BW; Lundman, P; Nicholls, SJ; Palmer, MK | 4 |
| Chen, X; Li, Y; Lin, L; Wang, S; Zhang, H | 1 |
| Li, CF; Wang, YZ; Yang, L | 1 |
| Abbasi, A; Bahrami, M; Farhad, N; Froushani, SMA; Zarei, L | 1 |
| Chen, L; He, M; Lai, B; Li, Z; Shyy, JY; Wang, Y; Yang, Y; Zhang, J | 1 |
| Bagga, A; Hari, P; Hari, S; Khandelwal, P; Lakshmy, R; Satpathy, A; Sinha, A; Thergaonkar, R | 1 |
| Brackett, CD; Ornstein, DL; Strait, AM | 1 |
| Pan, H; Rui, R; Sun, B; Wang, X; Zhang, L | 1 |
| Liu, G; Liu, M; Wang, M | 1 |
| Cheung, LK; Chow, DS; El-Zailik, A; Sherman, V; Wang, Y | 1 |
| Aquino, M; Baber, U; Barman, N; Camaj, A; Chandrasekhar, J; Claessen, B; Dangas, G; Faggioni, M; Farhan, S; Guedeney, P; Kalkman, DN; Kini, A; Kovacic, JC; Mehran, R; Moreno, P; Shah, S; Sharma, S; Sorrentino, S; Sweeny, J; Vijay, P; Vogel, B | 1 |
| Akimoto, H; Inoue, N; Kobayashi, D; Negishi, A; Numajiri, S; Ohshima, S; Okita, M; Oshima, S | 1 |
| Baomin, Z; Houshuai, T; Liping, Z; Tao, Y; Xiufang, L | 1 |
| Guo, J; Li, T; Liu, Y; Yao, Y; Zeng, Z; Zhang, R; Zhao, Y | 1 |
| Chen, Q; Fang, HY; Gong, R; Wu, YQ; Xiang, J; Xu, CC; Zhang, HZ | 1 |
| Guo, X; Li, X; Wang, L; Wang, P; Xia, X | 1 |
| Koszalka, P; Kutryb-Zajac, B; Slominska, EM; Smolenski, RT | 1 |
| Indumathi, B; Katkam, SK; Kutala, VK; Ramakumari, N | 1 |
| Chen, B; Chen, X; Cheng, D; Li, X; Lin, C; Sun, W; Wang, J; Wu, T; Xiao, H | 1 |
| Cannon, CP; Khan, I; Klimchak, AC; Reynolds, MR; Rosenson, RS; Sanchez, RJ; Sasiela, WJ | 1 |
| Christodoulou, E; Kadoglou, NPE; Kakisis, J; Kostomitsopoulos, NG; Liapis, CD; Paronis, E; Stasinopoulou, M; Valsami, G | 1 |
| Chan, P; Liu, Z; Ma, YB; Tomlinson, B; Zhang, Y | 1 |
| Faits, T; Jang, S; Johnson, WE; Lakshman, S; Lamon-Fava, S; Lichtenstein, AH; Matthan, NR; Molokin, A; Solano-Aguilar, G; Urban, JF; Walker, ME | 1 |
| Elseweidy, MM; Elswefy, SE; Tarek, S; Younis, NN | 1 |
| Chen, H; Chen, X; Chen, Y; Dong, J; Ge, J; Jiang, XC; Wang, L; Zhang, X | 1 |
| Cardozo, KHM; Carvalho, VM; Dariolli, R; Krieger, JE; Laurindo, FR; Malagrino, PA; Padilha, K; Pereira, ADC; Tanaka, LY; Venturini, G | 1 |
| Ding, Y; Gu, X; Hong, D; Xie, S | 1 |
| Cao, Z; Jin, H; Li, B; Liu, M; Shen, Z; Sun, X; Tian, Y; Zhang, T; Zhang, Z; Zhao, X | 1 |
| Feng, B; Li, PC; Wang, YR; Xu, L | 1 |
| Ardoin, SP; Barnhart, HX; Bowyer, SL; Brunner, HI; Eberhard, A; Evans, GW; Higgins, GC; Ilowite, NT; Imundo, LF; Jung, L; Kimura, Y; Klein-Gitelman, M; Levy, D; McCurdy, DK; Mieszkalski, KL; Punaro, L; Reed, AM; Sandborg, CI; Schanberg, LE; Sherry, DD; Silver, RM; Silverman, E; Singer, NG; Soep, JB; Thompson, SD; von Scheven, E; Wagner-Weiner, L; Wallace, C; Yow, E | 1 |
| Drechsler, M; Soehnlein, O; Weber, C | 1 |
| Feng, B; Li, X; Wang, H; Xu, L | 1 |
| Alexopoulos, N; Arepalli, CD; Chen, Z; Hartlage, GR; Kim, S; Melek, BH; Raggi, P; Stillman, AE | 1 |
| Ballet, S; Bini, J; Corot, C; Dickson, SD; Fayad, ZA; Izquierdo-Garcia, D; Klink, A; Lancelot, E; Mateo de Castro, J; Millon, A; Robert, P | 1 |
| Guo, RW; Heng, XH; Qi, F; Si, YK; Yang, LX; Zhou, XB | 1 |
| Gierman, LM; Huizinga, TW; Kloppenburg, M; Koudijs, A; Kühnast, S; Pieterman, EJ; Princen, HM; Stojanovic-Susulic, V; van Osch, GJ; Zuurmond, AM | 1 |
| Hou, XL; Liang, P; Zhang, Y; Zhang, YM | 1 |
| Gao, J; Gao, X; Pan, S | 1 |
| Chen, C; Liu, T; Shen, DZ; Xin, SL | 1 |
| Abdelbaky, A; Alon, A; Beals, CR; Dansky, H; Farkouh, ME; Fayad, ZA; Klimas, MT; Mogg, R; Nunes, IO; Rudd, JH; Shankar, SS; Subramanian, SS; Tawakol, A | 1 |
| Gerber, BL | 1 |
| Medvedeva, EA; Seleznev, EI; Shchukin, IuV | 1 |
| Alderson, P; Lewis, SR; Nicholson, A; Sanders, RD; Smith, AF | 1 |
| Delibas, N; Gocmen, AY; Gumuslu, S; Ocak, GA; Ozbilim, G | 1 |
| Laaksonen, R | 1 |
| Banach, M; Celecova, Z; Gaspar, L; Hirnerova, E; Huckova, N; Kucera, M; Oravec, S | 1 |
| Li, T; Liu, J; Sai, X; Sun, Y; Wang, D; Yang, B; Zhou, R | 1 |
| Cui, Y; Ju, SH; Li, KC; Lu, T; Teng, GJ; Wen, S | 1 |
| Fan, J; Keyamura, Y; Kohashi, M; Koyama, T; Niimi, M; Nozako, M; Yasufuku, R; Yoshikawa, T | 1 |
| Bash, D; Brennan, DM; Cavender, MA; Jukema, JW; Kastelein, JJ; Koenig, W; Lincoff, AM; Menon, V; Nambi, V; Nicholls, SJ; Nissen, SE; Rosenson, RS; Schwartz, GG; Wright, RS | 1 |
| Davoodpour, P; Larsson, L; Malm, J; Mörk, LM; Norata, GD; Parini, P; Rehnmark, S; Witt, MR | 1 |
| Ben-Yehuda, O; Constance, C; Hanson, ME; Lin, J; Lowe, RS; Tershakovec, AM; Wenger, NK; Zieve, F | 1 |
| Izuhara, M; Matsuda, M; Mitsuoka, H; Shioji, K; Uegaito, T | 1 |
| Fang, D; Jia, H; Qu, Z; Quan, W; Quan, Z; Yang, S | 1 |
| Abdelbary, A; Hamza, M; Unis, A | 1 |
| Chang, WT; Huang, SK; Liau, I; Yang, YC | 1 |
| Bauer, I; Bertolotto, M; Dallegri, F; Fabre, M; Galan, K; Lenglet, S; Mach, F; Montecucco, F; Nencioni, A; Palombo, D; Pane, B; Pelli, G; Pende, A; Python, M; Quercioli, A; Spinella, G; Vuilleumier, N | 1 |
| Simonyi, G | 1 |
| Chi, L; Hu, X; Pan, N; Peng, L; Zhang, Y | 2 |
| Bijl, M; de Leeuw, K; Kallenberg, CG; Limburg, PC; Souza, AW; Stegeman, CA; van Timmeren, MM; Westra, J | 1 |
| Anticoli, S; Gambardella, L; Malorni, W; Maselli, A; Matarrese, P; Panusa, A; Ruggieri, A; Vona, R | 1 |
| Imaizumi, A; Itabe, H; Keyamura, Y; Kohashi, M; Koyama, T; Nagano, C; Niimi, M; Nozako, M; Yasufuku, R; Yoshikawa, T | 1 |
| Chen, J; Chen, S; Huang, H; Huang, Y; Liu, P; Liu, Z; Shen, X; Xu, S | 1 |
| Cai, Y; Fan, Z; Feng, J; Jiang, F; Li, J; Liu, X; Ma, D; Zha, K; Zheng, S | 1 |
| Guo, YQ; Li, YF; Shi, ST; Wang, ZH | 1 |
| Bai, L; Chen, Y; Fan, J; Gao, S; Guan, H; Li, Y; Lin, Y; Liu, E; Wang, Y; Zhao, S; Zhu, N | 1 |
| Kuwano, T; Miura, S; Saku, K; Shimizu, T; Tanigawa, H; Uehara, Y; Zhang, B | 1 |
| Havekes, LM; Jukema, JW; Kühnast, S; Landmesser, U; Lüscher, TF; Pieterman, E; Princen, HM; Rensen, PC; Simic, B; van der Hoorn, JW; van der Tuin, SJ; van Klinken, JB; Willems van Dijk, K | 1 |
| Ahmadi, M; Bacot, S; Barone-Rochette, G; Broisat, A; Devoogdt, N; Dumas, LS; Fagret, D; Ghezzi, C; Lahoutte, T; Perret, P; Riou, LM; Slimani, L; Soubies, A; Toczek, J | 1 |
| Al Batran, R; Al-Bayaty, F; Al-Obaidi, MM; Ashrafi, A | 1 |
| Chngrian, GV; Mysyshin, MB; Semegen-Bodak, KV; Slaba, NA; Solomenchuk, TN | 1 |
| Guo, P; Luan, H; Sun, X; Wang, S; Wu, C; Zhang, X | 1 |
| Al Batran, R; Al-Bayaty, F; Al-Obaidi, MM; Hussain, SF; Mulok, TZ | 1 |
| Baguet, JP; Dias-Domingos, S; Gagnadoux, F; Janssens, JP; Joyeux-Faure, M; Launois, SH; Leftheriotis, G; Lévy, PA; Pepin, JL; Perrig, S; Stanke-Labesque, F; Tamisier, R; Trzepizur, W | 1 |
| Černe, D; Drevenšek, G; Janić, M; Lunder, M; Marc, J; Šabovič, M; Zupan, J | 1 |
| Chen, L; Fang, Q; Li, L; Wang, Y; Xu, Y; Yan, X | 1 |
| Ai, R; Chen, F; Li, G; Lu, WH; Tang, ZZ; Wu, XW | 1 |
| Sun, B; Yan, WJ; Zhang, WL; Zou, ZP | 1 |
| Abdallah, MA; Asker, Mel-S; Atteia, HH; El-Seweidy, MM; Eldahmy, SI | 1 |
| Dostal, E; Gaspar, L; Goliasch, G; Hofbauer, SL; Huber, K; Kastl, SP; Katsaros, KM; Krychtiuk, KA; Maurer, G; Oravec, S; Pfaffenberger, S; Pongratz, T; Speidl, WS; Wojta, J; Wonnerth, A | 1 |
| Buttari, B; Profumo, E; Rigano, R; Saso, L | 1 |
| Karpe, PA; Kumar, S; Malek, V; Patel, G; Sanghavi, M; Srinivasan, K; Tikoo, K | 1 |
| Eguchi, Y; Fujita, K; Honda, Y; Hyogo, H; Imajo, K; Kessoku, T; Kirikoshi, H; Mawatari, H; Nakajima, A; Nozaki, Y; Ogawa, Y; Ono, M; Saito, S; Sumida, Y; Taguri, M; Tomeno, W; Wada, K; Yoneda, M | 1 |
| Balaz, D; Ciccocioppo, R; Gaspar, L; Hirnerova, E; Komornikova, A; Kruzliak, P; Kucera, M; Oravec, S; Rodrigo, L; Sabaka, P; Sabo, J; Slezak, P; Zulli, A | 1 |
| Mouli, KC; Reddy, VS; Reddy, YM | 1 |
| Abdelbaky, A; Ballantyne, CM; Du, S; Ehlgen, A; Emami, H; Farkouh, ME; Farmer, M; Fayad, ZA; Hayes, W; Kim, J; Langenickel, TH; Li, L; Mohler, ER; Roth, E; Subramanian, S; Tawakol, A; Velasquez, L; Vucic, E | 1 |
| Chen, Y; Gong, Z; Guo, Y; Li, Q; Li, Y; Liu, X; Wang, Y; Weng, X; Yang, Q; You, Y; Zhang, R; Zhou, B; Zhu, X | 1 |
| Deng, L; Gong, L; Li, D; Li, Y; Qi, C; Wu, W; Zhang, C; Zhang, Q; Zhang, T; Zhang, Y | 1 |
| Rajamannan, NM | 1 |
| Liu, B; Liu, Y; Meng, K; Shi, H; Wu, B; Yu, K; Zeng, Q; Zhang, W; Zhao, X; Zhong, Y; Zhu, R | 1 |
| Hongcheng, F; Ming, D; Shaoyuan, C; Yulang, H | 1 |
| Adánez, G; Ayala, I; Castells, MT; García-Pérez, B; Martín, A; Sánchez-Polo, MT | 1 |
| Bai, L; Chen, Y; Fan, J; Gao, S; Guan, H; Li, Y; Lin, Y; Liu, E; Sun, L; Wang, Y; Zhao, S; Zhu, N | 1 |
| Freiberg, MS; Justice, A; Lo Re, V | 1 |
| Abbara, S; Fitch, KV; Grinspoon, SK; Hoffmann, U; Hwang, J; Ihenachor, EJ; Lo, J; Looby, SE; Lu, MT; Oh, J; Plutzky, J; Robbins, G; Tawakol, A; Wei, J; Zimmerman, CO | 1 |
| Sozer, V | 1 |
| Amarenco, P; Bangalore, S; DeMicco, DA; Fayyad, R; Kastelein, JJ; Laskey, R; Waters, DD | 1 |
| Banach, M; Bittner, V; Hovingh, GK; Kastelein, JJ; Lip, GY; Mikhailidis, DP; Ray, K; Rysz, J; Sahebkar, A; Serban, C; Undas, A; Ursoniu, S; Watts, GF | 1 |
| Amuzie, C; Denham, S; Mais, DE; Rogers, CS; Swart, JR; Vihtelic, T | 1 |
| Pantan, R; Suksamrarn, A; Tocharus, C; Tocharus, J | 1 |
| Daniels, AB; Eliott, D; Ganotakis, E; Goldfarb, JW; Gragoudas, ES; Kapsala, ZG; Kim, IK; Loewenstein, JI; Miller, JW; Tsilimbaris, MK; Vavvas, DG; Young, LH | 1 |
| Gjorstrup, P; Kleemann, R; Kooistra, T; Morrison, MC; Salic, K; Verschuren, L; Wielinga, PY; Wu, L | 1 |
| Aubry, T; Bourgeois, N; Desfontis, JC; Didier, R; Dubreuil, M; Gilard, M; Goanvec, C; Le Grand, Y; Mallem, Y; Mansourati, J; Pichavant-Rafini, K; Plee-Gautier, E; Roquefort, P; Theron, M; Tissier, F | 1 |
| Dong, J; Liao, L; Liu, F; Liu, J; Mou, Y; Shen, X; Yang, T; Zhou, X | 1 |
| Chang, YY; Hung, CS; Kao, HL; Lee, JK; Lin, HJ; Lin, YH; Lin, YM; Lin, YT; Wu, YW | 1 |
| Chen, Y; Han, H; Ni, J; Sun, J; Zhang, R; Zhu, J | 1 |
| Cho, L; Elshazly, M; Kapadia, S; King, P; Nicholls, SJ; Nissen, SE; Puri, R; Shao, M; Stegman, B; Tuzcu, M | 1 |
| Guo, Q; He, J; Jiang, C; Liu, J; Lu, J; Yang, Y; Zhang, W; Zhao, Y | 1 |
| Bjorndahl, TC; Caplice, NM; Fitzgerald, GF; London, LE; Mandal, R; Murphy, K; Ross, RP; Ryan, PM; Shanahan, F; Stanton, C; Wishart, DS | 1 |
| Chen, Y; Dai, YT; Tang, L; Yu, W; Zhang, Z | 1 |
| Caselli, S; Celotto, A; Cohen, A; De Castro, S; Di Angelantonio, E; Fiorelli, M; Marcantonio, A; Pandian, N; Papetti, F; Passaseo, I | 1 |
| Chae, A; Choi, SH; DeMaria, AN; Messig, M; Miller, E; Nissen, SE; Ntanios, F; Tsimikas, S; Witztum, JL | 1 |
| Cawley, PJ; Otto, CM | 1 |
| Avello L, M; Bravo D, M; Calvo M, C; Mennickent C, S | 1 |
| Forst, T; Fuchs, W; Hanefeld, M; Konrad, T; Lehmann, U; Müller, J; Pfützner, A; Schaper, F; Weber, M; Wilhelm, B | 1 |
| Annapurna, A; Reddy, YN; Srinivas, M | 1 |
| Basart, DC; Bots, ML; Evans, GW; Grobbee, DE; Kastelein, JJ; Sijbrands, EJ; Stalenhoef, AF; Stroes, ES; van Leuven, SI; Vergeer, M; Visseren, FL | 1 |
| Kurabayashi, M; Yamazaki, T | 1 |
| Argyropoulou, MI; Elisaf, M; Kiortsis, DN; Tselepis, AD; Tsouli, SG; Xydis, V | 1 |
| Blanco-Colio, LM; Egido, J; Ortiz, A; Rodrigues-Díez, R; Rodríguez-Vita, J; Ruiz-Ortega, M; Sánchez-Galán, E; Sánchez-López, E; Santamaría, B | 1 |
| Akar Bayram, N; Aydoğdu, S; Canbay, A; Diker, E; Durmaz, T; Kayhan, T; Keleş, T; Ozdemir, O; Sahin, D | 1 |
| Cheng, S; Ge, S; Liu, D; Liu, X; Xu, G; Xu, J; Zhou, G | 1 |
| Böger, R; Eggeling, S; Meinertz, T; Munzel, T; Ostad, MA; Schwedhelm, E; Tschentscher, P; Warnholtz, A; Wenzel, P | 1 |
| Creager, MA; Ganz, P; Liao, JK; Liu, PY; Nohria, A; Okamoto, R; Prsic, A; Selwyn, A | 1 |
| Amato, M; Arquati, M; Baldassarre, D; Brusoni, B; Camera, M; Cortellaro, M; Fiorentini, C; Montorsi, P; Porta, B; Romano, S; Tremoli, E; Veglia, F | 1 |
| Creager, MA; Donnelly, J; Ganz, P; Liao, JK; Liu, PY; Nohria, A; Rawlings, R; Selwyn, A | 1 |
| Gryglewski, R; Hassan, M; Heeba, G; Khalifa, M; Malinski, T; Moselhy, ME | 1 |
| Ayaori, M; Fayad, ZA; Kihara, T; Kusuhara, M; Momiyama, Y; Nagata, M; Nakamura, H; Nakaya, K; Ogura, M; Ohmori, R; Ohsuzu, F; Tamai, S; Tanaka, N; Taniguchi, H; Yonemura, A | 1 |
| Li, JJ; Li, XY; Li, Y; Qin, L; Yang, P | 1 |
| Arbustini, E; Gambarin, FI | 1 |
| Caruthers, SD; Lanza, GM; Wickline, SA; Williams, TA; Winter, PM; Zhang, H | 1 |
| Tokgözoğlu, L | 1 |
| Alcudia, JF; Badimon, L; Guadall, A; Martínez-González, J; Raposo, B; Rodríguez, C; Sánchez-Gómez, S | 1 |
| Aarts, JC; Bax, L; Beek, FJ; Beutler, JJ; Braam, B; Buskens, E; de Haan, MW; Doorenbos, CJ; Huysmans, FT; Kouwenberg, HJ; Kroon, AA; Mali, WP; Pattynama, PM; Plouin, PF; Postma, CT; Rabelink, TJ; Raynaud, A; Reekers, JA; Rutten, MJ; Schultze Kool, LJ; van de Ven, PJ; van den Meiracker, AH; van Montfrans, GA; Vroegindeweij, D; Woittiez, AJ | 1 |
| Chaiyaroj, SC; Chansrichavala, P; Chantharaksri, U; Sritara, P | 1 |
| Brcakova, E; Micuda, S; Nachtigal, P; Pospechova, K; Pospisilova, N; Semecky, V; Vecerova, L | 1 |
| Saito, Y; Yokote, K | 1 |
| Chiu, B; Fenster, A; Krasinski, A; Parraga, G; Spence, JD | 2 |
| Blann, AD; Goon, PK; Jaumdally, RJ; Lip, GY; Varma, C | 1 |
| Castelli, P; Castiglioni, L; Consuelo Maio, R; Cosentino, M; De Leo, A; Guasti, L; Lecchini, S; Legnaro, M; Marino, F; Maroni, L; Piffaretti, G; Rasini, E; Schembri, L; Tozzi, M; Venco, A | 1 |
| Aigbirhio, FI; Bird, JL; Davenport, AP; Davies, JR; Figg, N; Fryer, TD; Izquierdo-Garcia, D; Richards, HK; Rudd, JH; Warburton, EA; Weissberg, PL | 1 |
| Deng, JT; Hu, XY; Li, L; Liu, XL; Shang, YY; Wang, ZH; Zhang, LP; Zhang, W; Zhang, Y; Zhong, M | 1 |
| Aikawa, E; Figueiredo, JL; Hembrador, S; Keliher, E; Kelly, K; Libby, P; Nahrendorf, M; Panizzi, P; Weissleder, R; Zhang, H | 1 |
| Geng, L; Li, ZX; Meng, XP; Wang, SX; Yin, CY; Zhang, JC | 1 |
| Cheng, S; Ge, S; Liu, D; Liu, X; Liu, Z; Xu, G; Zhang, R; Zhou, G; Zhu, W | 1 |
| Feng, L; Jiang, J; Li, M; Ren, H; Zhang, Y; Zhu, X | 1 |
| Cairns, R; Cannon, CP; Michael Gibson, C; Nazer, B; Ray, KK | 1 |
| Cipollone, F; Faggin, E; Ganassin, L; Grego, F; Mezzetti, A; Pauletto, P; Plebani, M; Puato, M; Rattazzi, M; Zambon, A | 1 |
| Awad, J; Fenster, A; Krasinski, A; Parraga, G | 1 |
| Dougu, N; Nukui, T; Taguchi, Y; Takashima, S; Tanaka, K; Toyoda, S | 1 |
| Frank, PG; Lanza-Jacoby, S; Laury-Kleintop, L; Raval, M; Yan, G | 1 |
| Dhawan, V; Mahajan, N | 1 |
| Mombelli, G; Sirtori, CR | 1 |
| Akhlaghi, F; Asberg, A; Hermann, M; Narwal, R; Rosenbaum, SE | 1 |
| Antoniades, C; Antonopoulos, AS; Bakogiannis, C; Casadei, B; Channon, KM; Demosthenous, M; Economopoulos, G; Marinou, K; Miliou, A; Paschalis, A; Psarros, C; Reilly, S; Sfyras, N; Stefanadis, C; Tousoulis, D; Zhang, MH | 1 |
| Ahn, CW; Cha, BS; Kang, ES; Kang, SB; Lee, BW; Lee, HC; Moon, JH; Park, JS | 1 |
| Haron, MM; Houssen, ME; Ibrahim, TM; Metwally, SS | 1 |
| Abe, A; Katayama, Y; Katsura, K; Nagayama, H; Nishiyama, Y; Otsuka, T; Ueda, M | 1 |
| Biessen, EA; Bot, I; Jukema, JW; Lankhuizen, IM; van Berkel, TJ | 1 |
| Cámara, C; Costo, A; Crespo, L; Fernández Pereira, L; Pereira, G; Sánchez Muñoz-Torrero, JF | 1 |
| Christopher-Stine, L; Kiani, AN; Magder, LS; Petri, MA; Post, W | 1 |
| Insull, W; Jiang, P; Krause, S; Padley, RJ; Parreno, RA; Superko, HR; Thakkar, RB; Toth, PP | 1 |
| Antoniades, C; Koniari, K; Marinou, K; Miliou, A; Nikolopoulou, A; Noutsou, M; Papageorgiou, N; Stefanadi, E; Stefanadis, C; Tousoulis, D | 1 |
| Amano, T; Aoyama, T; Hayashi, M; Ishii, H; Matsubara, T; Murohara, T; Nishio, M; Takahashi, H; Tamaki, T; Tanaka, M; Toriyama, T; Yoshikawa, D | 1 |
| Andersson, KE; Eussen, SR; Garssen, J; Hellstrand, P; Klungel, OH; Oste, R; Rompelberg, CJ; van Kranen, H | 1 |
| Andrys, C; Brcakova, E; Micuda, S; Mullerova, Z; Nachtigal, P; Rathouska, J; Slanarova, M; Strasky, Z; Vecerova, L | 1 |
| Ballantyne, C; Barter, P; Borgman, M; Chapman, MJ; Erbel, R; Libby, P; Nicholls, SJ; Nissen, SE; Raichlen, JS | 1 |
| Bi, H; Chen, WA; Daugherty, A; Hong, B; Luo, Y; Wang, JA; Wang, Y; Xie, X; Zhang, S | 1 |
| Chen, H; Chu, B; Dong, L; Hatsukami, TS; Kerwin, WS; Neradilek, MB; Underhill, HR; Yuan, C; Zhao, XQ | 1 |
| Fujii, N; Inoue, H; Kameyama, T; Matsuki, A; Nozawa, T; Ohori, T; Shida, T; Sobajima, M; Suzuki, T | 1 |
| Blanco-Colio, LM; de Teresa, E; Després, JP; Egido, J; Farsang, C; Gaw, A; Gensini, GF; Gupta, M; Langer, A; Leiter, LA; Martineau, P; Tran, T | 1 |
| Afanas'eva, MI; Afanas'eva, OI; Ezhov, MV; Liakishev, AA; Pokrovskiĭ, SN; Safarova, MS; Tripoten', MI; Trukhacheva, EP | 1 |
| Nart, D; Onat, T; Sezer, ED; Sozmen, EY | 1 |
| Catapano, AL; Norata, GD; Pirillo, A | 1 |
| Barter, PJ; Boekholdt, SM; Breazna, A; Kastelein, JJ; Rye, KA; Tardif, JC; Waters, DD | 1 |
| Budinski, D; Gosho, M; Gumprecht, J; Hounslow, N | 1 |
| Drechsler, C; Genser, B; Hoffmann, MM; März, W; Wanner, C | 1 |
| Kiani, AN; Magder, LS; Petri, M; Post, WS | 1 |
| Chen, Z; Jia, F; Lu, G; Wu, C | 1 |
| Daida, H; Hibi, K; Hiro, T; Kimura, K; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ozaki, Y; Saito, S; Yamagishi, M; Yamaguchi, T | 1 |
| Gabriel, CL; Kastelein, JJ; Major, AS; Mendez-Fernandez, YV; Stroes, ES; Tak, PP; van Leuven, SI; Wade, NS; Wilhelm, AJ | 1 |
| Daemen, MJ; Gabriels, K; Gijbels, MJ; Heeneman, S; Hoving, S; Pol, JF; Russell, NS; Stewart, FA; te Poele, JA | 1 |
| Ravelli, A | 1 |
| Ardoin, SP; Barnhart, HX; Bowyer, SL; Brunner, HI; Eberhard, A; Evans, GW; Higgins, GC; Ilowite, NT; Imundo, LF; Jung, L; Kimura, Y; Klein-Gitelman, M; McCurdy, D; Mieszkalski, KL; Provenzale, J; Punaro, M; Reed, AM; Sandborg, C; Schanberg, LE; Sherry, DD; Silver, R; Silverman, E; Singer, NG; Soep, JB; Thompson, SD; von Scheven, E; Wagner-Weiner, L; Wallace, C; Yow, E | 1 |
| Brcakova, E; Micuda, S; Nachtigal, P; Rathouska, J; Slanarova, M; Strasky, Z; Vecerova, L | 1 |
| Bouma, BJ; de Groot, E; Groenink, M; Luijendijk, P; Mulder, BJ; Pieper, PG; Sieswerda, GT; van Dijk, AP; Veen, G; Vliegen, HW; Vriend, JW; Zwinderman, AH | 1 |
| Chen, MF; Chi, YC; Huang, CL; Huang, PJ; Kao, HL; Lin, HJ; Lin, LY; Lin, YH; Tzen, KY; Wang, YC; Wu, YW; Yang, WS; Yen, RF | 1 |
| Havekes, LM; Jukema, JW; Kühnast, S; Liau, G; Princen, HM; van den Hoek, AM; van der Hoorn, JW | 1 |
| Chapman, MJ | 1 |
| Hadoke, PW | 1 |
| Feig, JE; Fernandez-Hernando, C; Fisher, EA; Garabedian, MJ; Rotllan, N; Shamir, R; Shang, Y; Torra, IP; Vengrenyuk, Y; Wu, C | 1 |
| Choi, YJ; Geaney, JC; Karpf, DB; Krauss, RM; Naim, S; Roberts, BK; Wang, X; Wojnoonski, K | 1 |
| Bao, W; Benessiano, J; Mallat, Z; Olsson, AG; Ryu, SK; Schwartz, GG; Tedgui, A; Tsimikas, S | 1 |
| Schaefer, JR | 1 |
| Cao, HM; Feng, J; Li, GY; Li, J; Liu, B; Liu, M; Wang, Q | 1 |
| Alberti, PF; Conti, V; Corazzi, T; Falcinelli, E; Gresele, P; Miglietta, D; Minuz, P; Momi, S; Monopoli, A; Ongini, E | 1 |
| Nachtigal, P; Rathouska, J; Strasky, Z; Zemankova Vecerova, L | 1 |
| Chang, XR; Fu, L; He, XQ; Liu, M; Shang, LC; Yu, BS; Yuan, JL; Yue, ZH; Zhang, L | 1 |
| Böhm, M; Laufs, U; Schirmer, SH; Werner, CM | 1 |
| Goto, SN; Iwata, K; Takagi, H; Umemoto, T; Yamamoto, H | 1 |
| Cao, H; Cui, W; Du, B; Lin, S; Liu, Y; Qin, L; Xu, G | 1 |
| Bożentowicz-Wikarek, M; Chudek, J; Kocełak, P; Olszanecka-Glinianowicz, M; Smertka, M | 1 |
| Cetinkaya Demir, B; Köse, C; Ozbilgin, K; Uyar, Y | 1 |
| Doğru, MT; Ebinç, H; Sahin, O; Simşek, V; Tireli, E; Tulmac, M; Yildirim, N | 1 |
| Oĭnotkinova, OSh | 1 |
| Arazi, SS; Bernik, MM; Bertolami, M; Brion, MJ; Carracedo, A; Dorea, EL; Faludi, AA; Genvigir, FD; Hirata, MH; Hirata, RD; Rodrigues, AC; Sobrino, B; Willrich, MA | 1 |
| Armitage, J; Chen, F; Chen, YP; Chen, ZM; Feng, F; Gao, Y; Hopewell, JC; Hundei, WB; Jiang, LX; Landray, M; Li, J; Li, X; Liu, JM; Valdes-Marquez, E; Zhang, D; Zhang, HB | 1 |
| Berbée, JF; Havekes, LM; Hiemstra, PS; Khedoe, PP; Mol, IM; Princen, HM; Rensen, PC; Romijn, JA; Tsikas, D; van der Hoorn, JW; van Klinken, JB; Wang, Y; Wong, MC | 1 |
| DiNicolantonio, JJ; Lavie, CJ; O'Keefe, JH; Serebruany, VL | 1 |
| Arnaboldi, L; Baetta, R; Bellosta, S; Bonomo, A; Corsini, A; Ferri, N; Granata, A; Miglietta, D; Oliva, F; Ongini, E | 1 |
| Bubnova, MG | 1 |
| Kastelein, JJ; van Leuven, SI | 1 |
| Blanco-Colio, LM; Egido, J; Gómez-Hernández, A; Hernández, G; Martín-Ventura, JL; Muñoz-García, B; Ortega, L; Serrano, J; Tuñón, J; Vega, M | 1 |
| Ainsworth, CD; Beletsky, V; Blake, CC; Fenster, A; Spence, JD; Tamayo, A | 1 |
| Toth, PP | 1 |
| Ho, SS; Pal, S | 1 |
| Bley, S; Drexler, H; Grote, K; Grothusen, C; Luchtefeld, M; Schieffer, B; Selle, T; Tietge, UJ | 1 |
| Bao, S; Barter, PJ; Cutri, B; Kee, P; Nicholls, SJ; Rye, KA; Worthley, SG | 1 |
| Ceska, R; Malik, J; Stulc, T | 1 |
| Hori, M; Kaneto, H; Katakami, N; Kosugi, K; Matsuhisa, M; Sakamoto, K; Waki, H; Yamasaki, Y | 1 |
| Field, KM | 1 |
| Burnett, JR | 1 |
| Annovazzi, A; Arca, M; Bonanno, E; D'Alessandria, C; De Toma, G; Marcoccia, A; Scopinaro, F; Signore, A; Spagnoli, LG; Violi, F | 1 |
| Fusegawa, Y; Handa, S; Homma, Y; Oguma, T; Ozawa, H; Shiina, Y; Tanabe, T | 1 |
| Briestensky, J; Jamborova, G; Jaynes, R; Kopecky, M; Nachtigal, P; Pospechova, K; Pospisilova, N; Santar, I; Semecky, V; Smahelova, A; Solichova, D; Zdansky, P | 1 |
| Allen, C; Amabile, N; Barrios, V; Chen, JW; Johnson-Levonas, AO; Massaad, R; Paganelli, F; Vandormael, K | 1 |
| Bots, AF; Kastelein, JJ | 1 |
| Borges, JL | 1 |
| Blanco-Colio, LM; Egido, J; Gómez-Hernández, A; Hernández, G; Martín-Ventura, JL; Ortega, L; Ortego, M; Sánchez-Galán, E; Serrano, J; Tunón, J; Vega, M; Vidal, C | 1 |
| de Maat, M; Emeis, J; Havekes, L; Jukema, W; Maas, A; Offerman, E; Princen, H; Szalai, A; Trion, A; van der Laarse, A | 1 |
| Day, CA; Jacob, RF; Mason, RP; Walter, MF | 1 |
| Cai, YC; Fang, Y; Li, JQ; Li, P; Li, QZ; Wu, LR; Zhao, SP | 2 |
| Bailey, SR; Chandrasekar, B; Greene, WC; Imam, SZ; Mahimainathan, L; Mummidi, S; Patel, DN; Valente, AJ | 1 |
| Balla, J; Dorosz, J; Dulak, J; Jazwa, A; Jozkowicz, A; Loboda, A; Molema, G | 1 |
| Busser, E; de Kleijn, DP; de Vries, JP; Koekkoek, JA; Moll, FL; Pasterkamp, G; Schoneveld, A; van der Wal, AC; Velema, E; Verheijen, JH; Verhoeven, BA; Virmani, R | 1 |
| Aizawa, Y; Fukaya, H; Imaki, R; Izumi, T; Kubo, T; Ohtaki, K; Ozaki, K; Ozaki, S; Shinagawa, H | 1 |
| Jamborova, G; Nachtigal, P; Pospechova, K; Pospisilova, N; Semecky, V; Solichova, D; Zdansky, P | 1 |
| Mascitelli, L; Pezzetta, F | 1 |
| Blanco-Colio, LM; Duran, MC; Egido, J; Martín-Ventura, JL; Tuñon, J; Vivanco, F | 1 |
| Li, M; Ren, H; Zhang, Y; Zhu, X | 1 |
| Aukrust, P; Boullier, A; Breland, U; Damås, JK; Fevang, B; Frøland, SS; Gullestad, L; Halvorsen, B; Hansson, GK; Kjekshus, J; Ovchinnikova, O; Quehenberger, O; Robertson, AK; Sandberg, WJ; Smith, C; Taskén, K; Waehre, T; Yndestad, A; Øie, E | 1 |
| Barter, PJ; Bots, ML; Burgess, L; Duggan, WT; Evans, GW; Grobbee, DE; Kastelein, JJ; Kuivenhoven, JA; Revkin, JH; Riley, WA; Shear, CL; van Leuven, SI | 1 |
| Couderc, R; Cynober, L; Martin, C; Moinard, C; Rasmusen, C; Tricottet, V | 1 |
| Bots, ML; Evans, GW; Kastelein, JJ; Revkin, JH; Riley, WA; Shear, CL; van Leuven, SI | 1 |
| Kulbertus, H | 1 |
| Mazzone, T | 1 |
| Bray, F; Chu, B; Dodge, JT; Hatsukami, TS; Lee, CD; Moore, AB; Phan, BA; Polissar, NL; Yuan, C; Zhao, XQ | 1 |
| Das, S; Gidding, SS; Mitchell, D; Zhang, S | 1 |
| Chiu, B; Egger, M; Fenster, A; Parraga, G; Spence, JD | 1 |
| Cuccurullo, F; Di Febbo, C; Di Nisio, M; Guglielmi, MD; Moretta, V; Porreca, E; Stuppia, L | 1 |
| Jankl, S; Kofler, S; Nickel, T; Schlichting, C; Weis, M | 1 |
| Averna, MR; Bucciarelli, L; Cefalù, AB; Ciabattoni, G; Davì, G; Davì, V; Ferrante, E; Noto, D; Pettinella, C; Santilli, F | 1 |
| Kaminnĭ, AI; Kukharchuk, VV | 1 |
| Badimon, JJ; Chew, DP; Corti, R; Fallon, JT; Fayad, ZA; Fuster, V; Helft, G; Worthley, MI; Worthley, SG; Zaman, AG | 1 |
| de Haan, W; de Vries-van der Weij, J; Gautier, T; Havekes, LM; Jukema, JW; Princen, HM; Rensen, PC; Romijn, JA; van der Hoogt, CC; van der Hoorn, JW; Westerterp, M | 1 |
| Bujo, H; Hanaoka, H; Kodama, T; Mikami, K; Miyashita, Y; Nishikawa, T; Saito, Y; Shinomiya, M; Tada, N; Yokote, K | 1 |
| Akalin, A; Akcar, N; Sensoy, B; Temiz, G | 1 |
24 review(s) available for atorvastatin and Atherogenesis
| Article | Year |
|---|---|
Synergistic actions between angiotensin-converting enzyme inhibitors and statins in atherosclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Renin-Angiotensin System | 2022 |
Pharmacological interventions for asymptomatic carotid stenosis.
Topics: Aspirin; Atherosclerosis; Atorvastatin; Carotid Stenosis; Chlorthalidone; Fluvastatin; Hemorrhage; Humans; Ischemic Stroke; Metoprolol; Pravastatin; Probucol; Rosuvastatin Calcium; Stroke; Warfarin | 2023 |
Effect of atorvastatin treatment on circulating adiponectin: a meta-analysis of randomized controlled trials.
Topics: Adiponectin; Atherosclerosis; Atorvastatin; Body Mass Index; Dose-Response Relationship, Drug; Humans; Randomized Controlled Trials as Topic | 2019 |
Critical Review on the Analytical Techniques for the Determination of the Oldest Statin-Atorvastatin-in Bulk, Pharmaceutical Formulations and Biological Fluids.
Topics: Atherosclerosis; Atorvastatin; Cholesterol, LDL; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Drug Compounding; Electrophoresis, Capillary; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Spectrophotometry | 2017 |
Modeling Statin-Induced Reductions of Cardiovascular Events in Primary Prevention: A VOYAGER Meta-Analysis.
Topics: Aged; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Databases, Factual; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Least-Squares Analysis; Male; Middle Aged; Odds Ratio; Practice Guidelines as Topic; Primary Prevention; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium | 2018 |
Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Risk Factors; Simvastatin | 2019 |
Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70 mg/dl or ≥ 50% reduction in high-risk patients: results from VOYAGER.
Topics: Aged; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Risk Reduction Behavior; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2013 |
Perioperative statin therapy for improving outcomes during and after noncardiac vascular surgery.
Topics: Adult; Angioplasty; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cause of Death; Cholestyramine Resin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Perioperative Care; Postoperative Complications; Pyrroles; Randomized Controlled Trials as Topic; Sitosterols; Vascular Surgical Procedures | 2013 |
Pleiotropic effects of statins in atherosclerotic disease: focus on the antioxidant activity of atorvastatin.
Topics: Antioxidants; Atherosclerosis; Atorvastatin; Heptanoic Acids; Humans; Pyrroles | 2014 |
To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis.
Topics: Adolescent; Adult; Aged; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Databases, Factual; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Least-Squares Analysis; Male; Middle Aged; Odds Ratio; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Simvastatin; Young Adult | 2015 |
Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis.
Topics: Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Rosuvastatin Calcium; Simvastatin | 2016 |
The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials.
Topics: Adult; Aged; Antigens; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Thrombosis; von Willebrand Factor; Young Adult | 2016 |
Prevention of calcific aortic valve stenosis-fact or fiction?
Topics: Angiotensin-Converting Enzyme Inhibitors; Aortic Valve Stenosis; Atherosclerosis; Atorvastatin; Calcinosis; Cardiomyopathies; Disease Progression; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Renin-Angiotensin System | 2009 |
[Pleiotropic effects of statins].
Topics: Anticholesteremic Agents; Antioxidants; Atherosclerosis; Atorvastatin; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Oxidative Stress; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
[Dyslipidemia, atherosclerosis, and vulnerable plaques: the effect of atorvastatin on atherosclerosis and plaque structure].
Topics: Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors | 2009 |
Pitavastatin: novel effects on lipid parameters.
Topics: Apolipoprotein A-I; Apolipoproteins B; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Coronary Artery Disease; Double-Blind Method; Dyslipidemias; Europe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Lipids; Multicenter Studies as Topic; Plaque, Atherosclerotic; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Russia; Simvastatin; Triglycerides | 2011 |
[HDL level or HDL function as the primary target in preventive cardiology].
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Early Termination of Clinical Trials; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Membrane Transport Proteins; Myocardial Infarction; Niacin; Pyrimidines; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Reference Values; Rosuvastatin Calcium; Scavenger Receptors, Class B; Sulfonamides; Survival Rate; Up-Regulation | 2012 |
The role of endoglin in atherosclerosis.
Topics: Animals; Antigens, CD; Atherosclerosis; Atorvastatin; Endoglin; Endothelium, Vascular; Heptanoic Acids; Humans; Hypercholesterolemia; Mice; Nitric Oxide Synthase Type III; Plaque, Atherosclerotic; Proteoglycans; Pyrroles; Receptors, Cell Surface; Receptors, Transforming Growth Factor beta; Swine | 2012 |
Effects of atorvastatin on carotid intima media thickness: a meta-analysis of randomized controlled trials.
Topics: Atherosclerosis; Atorvastatin; Carotid Intima-Media Thickness; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Statin wars: the heavyweight match--atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease.
Topics: Atherosclerosis; Atorvastatin; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides | 2013 |
Atorvastatin.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; Coronary Artery Disease; Drug Interactions; Endothelium, Vascular; Forecasting; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes; Pravastatin; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic | 2005 |
New insights in the treatment of dyslipidemia: a focus on cardiovascular event reduction and the anti-atherosclerotic effects of atorvastatin.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol; Dyslipidemias; Heptanoic Acids; Humans; Pyrroles; Risk Factors | 2005 |
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
Topics: Animals; Atherosclerosis; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pravastatin; Pyrroles; Risk Factors; Simvastatin | 2005 |
Vascular protection of dual therapy (atorvastatin-amlodipine) in hypertensive patients.
Topics: Amlodipine; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Calcium Channel Blockers; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypertension; Pyrroles | 2006 |
74 trial(s) available for atorvastatin and Atherogenesis
| Article | Year |
|---|---|
Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.
Topics: Adult; Atherosclerosis; Atorvastatin; Double-Blind Method; Humans; Myocardial Infarction; Oxazolidinones; Treatment Outcome | 2022 |
Effect of different doses of atorvastatin on collateral formation in coronary artery disease patients with coronary atherosclerosis.
Topics: Atherosclerosis; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Humans; Lipids; Tumor Necrosis Factor-alpha | 2022 |
Rationale and design of a randomised double-blind 2×2 factorial trial comparing the effect of a 3-month intensive statin and antiplatelet therapy for patients with acute mild ischaemic stroke or high-risk TIA with intracranial or extracranial atherosclero
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Atorvastatin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Ischemic Stroke; Middle Aged; Platelet Aggregation Inhibitors; Stroke | 2023 |
Effects of amlodipine combined with atorvastatin on Th17/Treg imbalance and vascular microcirculation in hypertensive patients with atherosclerosis: A double-blind, single-center randomized controlled trial.
Topics: Amlodipine; Atherosclerosis; Atorvastatin; Carotid Artery Diseases; Humans; Hypertension; Microcirculation; Receptors, Retinoic Acid; RNA; T-Lymphocytes, Regulatory; Th17 Cells | 2023 |
Effect of atorvastatin on subclinical atherosclerosis in virally-suppressed HIV-infected patients with CMV seropositivity: a randomized double-blind placebo-controlled trial.
Topics: Atherosclerosis; Atorvastatin; Carotid Intima-Media Thickness; Cholesterol, LDL; Cytomegalovirus Infections; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2021 |
Forty-eight weeks of statin therapy for type 2 diabetes mellitus patients with lower extremity atherosclerotic disease: Comparison of the effects of pitavastatin and atorvastatin on lower femoral total plaque areas.
Topics: Aged; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Femur; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lower Extremity; Male; Middle Aged; Plaque, Atherosclerotic; Quinolines; Treatment Outcome | 2021 |
Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Benzodiazepines; Biomarkers; Cholesterol Ester Transfer Proteins; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Lipids; Male; Middle Aged; Time Factors; Treatment Outcome; United States | 2017 |
Effect of Combination Therapy of Ezetimibe and Atorvastatin on Remnant Lipoprotein Versus Double Atorvastatin Dose in Egyptian Diabetic Patients.
Topics: Anticholesteremic Agents; Apolipoproteins B; Atherosclerosis; Atorvastatin; Cholesterol; Cholesterol, LDL; Diabetes Mellitus; Drug Therapy, Combination; Egypt; Ezetimibe; Female; Gastric Stump; Humans; Lipoproteins; Male; Middle Aged; Prospective Studies; Triglycerides | 2018 |
Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
Topics: Aged; Angina, Unstable; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Female; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Patient Care Planning; PCSK9 Inhibitors; Rosuvastatin Calcium; Stroke; Treatment Outcome | 2017 |
Statins reduce the expressions of Tim-3 on NK cells and NKT cells in atherosclerosis.
Topics: Adult; Aged; Atherosclerosis; Atorvastatin; CD3 Complex; Cholesterol; Female; Hepatitis A Virus Cellular Receptor 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Killer Cells, Natural; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Natural Killer T-Cells; Rosuvastatin Calcium; T-Lymphocytes | 2018 |
Drug effect of atorvastatin on middle cerebral atherosclerotic stenosis and high resolution NMR diagnosis.
Topics: Aged; Atherosclerosis; Atorvastatin; Constriction, Pathologic; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Magnetic Resonance Imaging; Male; Middle Aged; Middle Cerebral Artery; Pravastatin; Rosuvastatin Calcium; Simvastatin | 2018 |
Effect of atorvastatin on dyslipidemia and carotid intima-media thickness in children with refractory nephrotic syndrome: a randomized controlled trial.
Topics: Adolescent; Atherosclerosis; Atorvastatin; Carotid Arteries; Carotid Intima-Media Thickness; Child; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nephrotic Syndrome; Prospective Studies; Serum Albumin, Human; Treatment Outcome | 2018 |
Comparison and analysis of the therapeutic effect of different statins in the treatment of atherosclerosis.
Topics: Adult; Aged; Atherosclerosis; Atorvastatin; Carotid Arteries; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthase; Plaque, Atherosclerotic; Pravastatin; Simvastatin | 2018 |
Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein.
Topics: Adolescent; Age Factors; Atherosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Carotid Arteries; Carotid Intima-Media Thickness; Cholesterol, LDL; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Male; Prospective Studies; Puberty; Pyrroles; Treatment Outcome | 2014 |
Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: a substudy of the BELLES trial (Beyond Endorsed Lipid Lowering with EBT Scanning).
Topics: Adipose Tissue; Aged; Aged, 80 and over; Atherosclerosis; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Postmenopause; Pravastatin; Pyrroles; Vascular Calcification | 2013 |
Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study.
Topics: Adult; Aged; Aged, 80 and over; Aorta, Thoracic; Atherosclerosis; Atorvastatin; Carotid Arteries; Double-Blind Method; Feasibility Studies; Female; Fluorodeoxyglucose F18; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Multimodal Imaging; Plaque, Atherosclerotic; Positron-Emission Tomography; Pyrroles; Treatment Outcome | 2013 |
[Prevention of cardiovascular complications in patients undergoing aortic-iliac reconstructions by correction of inflammation and endotoxemia].
Topics: Aorta, Abdominal; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Endotoxemia; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iliac Artery; Inflammation; Middle Aged; Postoperative Complications; Pyrroles; Treatment Outcome; Vascular Surgical Procedures | 2013 |
Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.
Topics: Acetates; Acute Coronary Syndrome; Aged; Angina, Unstable; Atherosclerosis; Atorvastatin; Double-Blind Method; Early Termination of Clinical Trials; Female; Heptanoic Acids; Humans; Indoles; Keto Acids; Male; Middle Aged; Myocardial Infarction; Phospholipases A; Phospholipases A2, Secretory; Pyrroles; Risk; Stroke; Survival Analysis; Treatment Outcome | 2014 |
Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects ≥65 years.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Azetidines; Canada; Cholesterol, LDL; Double-Blind Method; Europe; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Treatment Outcome | 2014 |
Achievement rates of Japan Atherosclerosis Society Guidelines 2007 LDL-cholesterol goals with rosuvastatin or atorvastatin in patients who had not achieved their goal with atorvastatin.
Topics: Aged; Atherosclerosis; Atorvastatin; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Drug Substitution; Dyslipidemias; Female; Fluorobenzenes; Guideline Adherence; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Societies, Medical; Sulfonamides; Time Factors; Treatment Outcome | 2014 |
Response to statin therapy in obstructive sleep apnea syndrome: a multicenter randomized controlled trial.
Topics: Adult; Aged; Atherosclerosis; Atorvastatin; Blood Pressure; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Sleep Apnea, Obstructive | 2014 |
LDL-migration index (LDL-MI), an indicator of small dense low-density lipoprotein (sdLDL), is higher in non-alcoholic steatohepatitis than in non-alcoholic fatty liver: a multicenter cross-sectional study.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Azetidines; Cross-Sectional Studies; Ezetimibe; Female; Heptanoic Acids; Humans; Lipoproteins, LDL; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pyrroles; Risk Factors | 2014 |
The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trial.
Topics: Aged; Anti-Inflammatory Agents; Aortic Diseases; Atherosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Carotid Artery Diseases; Double-Blind Method; Female; Fluorodeoxyglucose F18; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Male; Middle Aged; Multimodal Imaging; p38 Mitogen-Activated Protein Kinases; Plaque, Atherosclerotic; Positron-Emission Tomography; Predictive Value of Tests; Protein Kinase Inhibitors; Pyrroles; Radiopharmaceuticals; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Triazines; United States | 2015 |
Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Amino Acids; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Coronary Vessels; Double-Blind Method; Female; HIV Infections; Humans; Male; Middle Aged; Plaque, Atherosclerotic; Treatment Outcome | 2015 |
2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?
Topics: Aged; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Prognosis; Simvastatin | 2016 |
Effects of 12 weeks of atorvastatin therapy on myocardial fibrosis and circulating fibrosis biomarkers in statin-naïve patients with hypertension with atherosclerosis.
Topics: Aged; Atherosclerosis; Atorvastatin; Biomarkers; Electrocardiography; Female; Fibrosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Myocardium | 2016 |
Coronary atheroma progression rates in men and women following high-intensity statin therapy: A pooled analysis of REVERSAL, ASTEROID and SATURN.
Topics: Adolescent; Adult; Aged; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Rosuvastatin Calcium; Sex Factors; Treatment Outcome; Young Adult | 2016 |
Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk.
Topics: Aged; Atherosclerosis; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Carotid Artery, Common; Double-Blind Method; Drug Therapy, Combination; Female; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Lipids; Male; Microcirculation; Middle Aged; Pioglitazone; Prospective Studies; Pyrroles; Radial Artery; Risk Assessment; Skin; Thiazolidinediones; Treatment Outcome; Ultrasonography | 2008 |
Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Pressure; Cholesterol Ester Transfer Proteins; Female; Heptanoic Acids; Humans; Male; Middle Aged; Mineralocorticoids; Pyrroles; Quinolines | 2008 |
Superior benefit of aggressive lipid-lowering therapy for high- risk patients using statins: the SUBARU study--more hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy.
Topics: Adult; Aged; Aged, 80 and over; Atherosclerosis; Atorvastatin; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels.
Topics: Analysis of Variance; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Drug Administration Schedule; Female; Health Care Costs; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Statistics, Nonparametric; Treatment Outcome | 2008 |
Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Azetidines; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome | 2009 |
Statins inhibit Rho kinase activity in patients with atherosclerosis.
Topics: Aged; Atherosclerosis; Atorvastatin; C-Reactive Protein; Cholesterol; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Placebos; Pyrroles; rho-Associated Kinases; Signal Transduction; Time Factors | 2009 |
Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment.
Topics: Aged; Atherosclerosis; Atorvastatin; Biomarkers; Blood Coagulation; Carotid Artery Diseases; Coronary Disease; Cross-Sectional Studies; Endothelium, Vascular; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Middle Aged; Myocardial Infarction; Plasma; Pyrroles; Sample Size; Thrombosis; Ultrasonography | 2009 |
Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event.
Topics: Aged; Atherosclerosis; Atorvastatin; Brachial Artery; Cholesterol, LDL; Double-Blind Method; Endothelium, Vascular; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Regional Blood Flow; rho-Associated Kinases; Rosuvastatin Calcium; Sulfonamides; White People | 2009 |
Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques: a 2-year follow-up by noninvasive MRI.
Topics: Aged; Aorta, Abdominal; Aorta, Thoracic; Aortic Diseases; Aortography; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Magnetic Resonance Angiography; Male; Middle Aged; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome | 2009 |
Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial.
Topics: Aged; Antihypertensive Agents; Aspirin; Atherosclerosis; Atorvastatin; Combined Modality Therapy; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Middle Aged; Pyrroles; Renal Artery; Renal Artery Obstruction; Stents | 2009 |
Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus: subanalysis of the collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study).
Topics: Atherosclerosis; Atorvastatin; Diabetes Mellitus, Type 2; Glucose Intolerance; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Quinolines; Treatment Outcome | 2009 |
Three-dimensional ultrasound quantification of intensive statin treatment of carotid atherosclerosis.
Topics: Aged; Atherosclerosis; Atorvastatin; Carotid Artery, Common; Carotid Stenosis; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Interpretation, Computer-Assisted; Male; Middle Aged; Pyrroles; Tunica Intima; Tunica Media; Ultrasonography | 2009 |
Pleiotropic effects of atorvastatin on monocytes in atherosclerotic patients.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Administration, Oral; Anticholesteremic Agents; Apoptosis; Atherosclerosis; Atorvastatin; CD13 Antigens; Coronary Disease; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Gene Expression; Heptanoic Acids; Humans; Lipid Metabolism; Male; Matrix Metalloproteinase 1; Middle Aged; Monocytes; Prolyl Oligopeptidases; Pyrroles; Receptors, Leptin; Reverse Transcriptase Polymerase Chain Reaction; Serine Endopeptidases; Time Factors; Treatment Outcome | 2010 |
[Effects of probucol, aspirin and atorvastatin combination therapy upon atherosclerosis].
Topics: Aged; Aspirin; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypolipidemic Agents; Lipoproteins, LDL; Male; Matrix Metalloproteinase 9; Middle Aged; Probucol; Pyrroles | 2009 |
Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atherosclerosis; Atorvastatin; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Observation; Pravastatin; Pyrroles; Treatment Outcome | 2010 |
Atorvastatin reduces macrophage accumulation in atherosclerotic plaques: a comparison of a nonstatin-based regimen in patients undergoing carotid endarterectomy.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Cholestyramine Resin; Endarterectomy, Carotid; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lymphocyte Count; Macrophages; Male; Pyrroles; Sitosterols | 2010 |
Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity.
Topics: Aged; Atherosclerosis; Atorvastatin; Coronary Artery Bypass; Double-Blind Method; Enzyme Activation; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; NADPH Oxidases; Organ Culture Techniques; Oxidation-Reduction; Preoperative Care; Pyrroles; rac1 GTP-Binding Protein; Saphenous Vein; Superoxides | 2010 |
Statin treatment decreased serum asymmetric dimethylarginine (ADMA) levels in ischemic stroke patients.
Topics: Aged; Aged, 80 and over; Arginine; Atherosclerosis; Atorvastatin; Brain Ischemia; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Linear Models; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Quinolines; Stroke | 2011 |
Lupus Atherosclerosis Prevention Study (LAPS).
Topics: Adolescent; Adult; Aged; Atherosclerosis; Atorvastatin; Carotid Artery Diseases; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Male; Middle Aged; Pyrroles; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography; Young Adult | 2011 |
Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Magnetic Resonance Spectroscopy; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Treatment Outcome; United States | 2010 |
Impact of 6 weeks of treatment with low-dose metformin and atorvastatin on glucose-induced changes of endothelial function in adults with newly diagnosed type 2 diabetes mellitus: A single-blind study.
Topics: Atherosclerosis; Atorvastatin; Blood Flow Velocity; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Female; Glucose; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Plethysmography; Pyrroles; Single-Blind Method; Treatment Outcome; Vasodilation | 2010 |
Comparison of atorvastatin 5 and 20 mg/d for reducing F-18 fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed tomography: a randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Aorta; Atherosclerosis; Atorvastatin; Dose-Response Relationship, Drug; Dyslipidemias; Female; Femoral Artery; Fluorodeoxyglucose F18; Heptanoic Acids; Humans; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Pyrroles; Treatment Outcome | 2010 |
Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN).
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Disease Progression; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ultrasonography | 2011 |
Carotid artery atherosclerosis: effect of intensive lipid therapy on the vasa vasorum--evaluation by using dynamic contrast-enhanced MR imaging.
Topics: Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Artery Diseases; Contrast Media; Female; Gadolinium DTPA; Heptanoic Acids; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Prognosis; Pyrroles; Treatment Outcome; Vasa Vasorum | 2011 |
Low-density lipoprotein cholesterol and high-sensitivity C-reactive protein lowering with atorvastatin in patients of South Asian compared with European origin: insights from the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACT
Topics: Aged; Asian People; Atherosclerosis; Atorvastatin; Body Mass Index; C-Reactive Protein; Case-Control Studies; Cholesterol, LDL; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Monitoring; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Life Style; Male; Middle Aged; Pyrroles; Risk; White People | 2012 |
[Pleiotropic effects of nicotinic acid therapy in men with coronary heart disease and elevated lipoprotein(a) levels].
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Atherosclerosis; Atorvastatin; Carotid Arteries; Coronary Artery Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipid Metabolism; Lipoprotein(a); Male; Middle Aged; Niacin; Plasminogen Activator Inhibitor 1; Pyrroles; Treatment Outcome; Tunica Intima | 2011 |
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Glycated Hemoglobin; Heptanoic Acids; Homeostasis; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines | 2011 |
Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Quinolines; Treatment Outcome; Young Adult | 2011 |
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and cardiovascular risk and efficacy of atorvastatin among subjects with diabetes on dialysis: the 4D study.
Topics: Aged; Analysis of Variance; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Double-Blind Method; Female; Genetic Predisposition to Disease; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinesins; Logistic Models; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Treatment Outcome | 2011 |
Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Calcium; Carotid Artery Diseases; Carotid Intima-Media Thickness; Comorbidity; Coronary Vessels; Disease Progression; Female; Heptanoic Acids; Humans; Lupus Erythematosus, Systemic; Male; Maryland; Pyrroles | 2011 |
Clinically evident polyvascular disease and regression of coronary atherosclerosis after intensive statin therapy in patients with acute coronary syndrome: serial intravascular ultrasound from the Japanese assessment of pitavastatin and atorvastatin in ac
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Atherosclerosis; Atorvastatin; Chi-Square Distribution; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prospective Studies; Pyrroles; Quinolines; Regression Analysis; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2011 |
Use of atorvastatin in systemic lupus erythematosus in children and adolescents.
Topics: Adolescent; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Intima-Media Thickness; Child; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Lipids; Lupus Erythematosus, Systemic; Male; Pyrroles; Treatment Outcome; Young Adult | 2012 |
Rationale and design of a trial on the effect of high dose statins on cardiovascular risk in adults after successful coarctation repair.
Topics: Adult; Aortic Coarctation; Atherosclerosis; Atorvastatin; Cardiac Surgical Procedures; Carotid Arteries; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; History, Ancient; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Postoperative Care; Prospective Studies; Pyrroles; Treatment Outcome; Ultrasonography | 2012 |
The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers.
Topics: Abdominal Fat; Adult; Aged; Anti-Inflammatory Agents; Arteritis; Atherosclerosis; Atorvastatin; Biomarkers; Calcium; Female; Fluorodeoxyglucose F18; Heptanoic Acids; Humans; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Pyrroles; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Vascular Calcification | 2012 |
Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia.
Topics: Acetates; Analysis of Variance; Atherosclerosis; Atorvastatin; Biomarkers; Chi-Square Distribution; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Obesity; Overweight; Particle Size; PPAR gamma; Pyrroles; Time Factors; Treatment Outcome; Triazoles | 2012 |
Effects of rosuvastatin versus atorvastatin on rho-associated coiled-coil containing protein kinase activity and endothelial function in patients with atherosclerosis.
Topics: Atherosclerosis; Atorvastatin; C-Reactive Protein; Endothelium, Vascular; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Phosphorylation; Protein Subunits; Pyrimidines; Pyrroles; rho-Associated Kinases; Rosuvastatin Calcium; Sulfonamides; Vasodilation | 2011 |
Single high dose atorvastatin does not ameliorate endothelial function and large arterial stiffness in dyslipidemic patients without atherosclerosis.
Topics: Adult; Aged; Atherosclerosis; Atorvastatin; Dyslipidemias; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Vascular Stiffness; Vasodilation | 2012 |
Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month.
Topics: Aged; Anti-Inflammatory Agents; Atherosclerosis; Atorvastatin; Blotting, Southern; Blotting, Western; Carotid Arteries; Chemokine CCL2; Cyclooxygenase 2; Dinoprostone; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Processing, Computer-Assisted; Immunohistochemistry; Inflammation; Leukocytes, Mononuclear; Lipids; Male; Middle Aged; NF-kappa B; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2005 |
3D ultrasound measurement of change in carotid plaque volume: a tool for rapid evaluation of new therapies.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Pressure; Carotid Stenosis; Cohort Studies; Double-Blind Method; Evaluation Studies as Topic; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Placebos; Pyrroles; Regression Analysis; Research Design; Risk Factors; Time Factors; Ultrasonography | 2005 |
Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Atherosclerosis; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Europe; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Taiwan; Treatment Outcome | 2005 |
Achieving lipid goals in real life: the Dutch DISCOVERY study.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Netherlands; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines | 2007 |
Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis.
Topics: Adolescent; Adult; Aged; Algorithms; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Arteries; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Male; Middle Aged; Models, Biological; Pyrroles; Quinolines; Research Design; Tunica Intima; Ultrasonography | 2007 |
Testing the hypothesis of atherosclerotic plaque lipid depletion during lipid therapy by magnetic resonance imaging: study design of Carotid Plaque Composition Study.
Topics: Allylamine; Atherosclerosis; Atorvastatin; Carotid Stenosis; Colesevelam Hydrochloride; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypolipidemic Agents; Lipid Metabolism; Magnetic Resonance Imaging; Male; Middle Aged; Niacin; Prospective Studies; Pyrroles | 2007 |
Mapping spatial and temporal changes in carotid atherosclerosis from three-dimensional ultrasound images.
Topics: Aged; Atherosclerosis; Atorvastatin; Carotid Artery, Common; Carotid Stenosis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Male; Middle Aged; Pyrroles; Treatment Outcome; Ultrasonography | 2008 |
Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins.
Topics: Anticholesteremic Agents; Arginine; Atherosclerosis; Atorvastatin; Cross-Sectional Studies; Dinoprost; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthase; Pravastatin; Pyrroles; Receptor for Advanced Glycation End Products; Receptors, Immunologic | 2007 |
Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis preventi
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Body Mass Index; Body Weight; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Japan; Male; Middle Aged; Pyrroles; Quinolines; Waist Circumference | 2008 |
246 other study(ies) available for atorvastatin and Atherogenesis
| Article | Year |
|---|---|
Pioglitazone combined with atorvastatin promotes plaque stabilization in a rabbit model.
Topics: Animals; Atherosclerosis; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Matrix Metalloproteinase 9; Pioglitazone; Plaque, Atherosclerotic; Rabbits; Triglycerides | 2022 |
A comparison of the effects of monotherapy with rosuvastatin, atorvastatin or ezetimibe versus combination treatment with rosuvastatin-ezetimibe and atorvastatin-ezetimibe on the integrity of vascular endothelial cells damaged by oxidized cholesterol.
Topics: Atherosclerosis; Atorvastatin; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Gene Expression Regulation; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; Occludin; Risk Factors; Rosuvastatin Calcium; Zonula Occludens-1 Protein | 2021 |
Atorvastatin Promotes Macrocalcification, But Not Microcalcification in Atherosclerotic Rabbits: An 18F-NaF PET/CT Study.
Topics: Animals; Aorta, Abdominal; Atherosclerosis; Atorvastatin; Calcium; Disease Models, Animal; Fluorine Radioisotopes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Positron Emission Tomography Computed Tomography; Rabbits; Radiopharmaceuticals; Sodium Fluoride; Vascular Calcification | 2021 |
Pleiotropic effects of pitavastatin: a pilot study using the saphenous vein endothelial cell model of endothelial injury and prevention of atherosclerosis.
Topics: Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cytokines; Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Pilot Projects; Quinolines; Saphenous Vein; Tumor Necrosis Factor-alpha | 2022 |
The role of cytokines, adhesion molecules, and toll-like receptors in atherosclerosis progression: the effect of Atorvastatin.
Topics: Animals; Atherosclerosis; Atorvastatin; Cell Adhesion Molecules; Cholesterol; Cytokines; Interleukin-17; Male; Rabbits; Toll-Like Receptors; Vascular Cell Adhesion Molecule-1 | 2022 |
Cardiac Alarmins as Residual Risk Markers of Atherosclerosis under Hypolipidemic Therapy.
Topics: Alarmins; Animals; Annexin A1; Atherosclerosis; Atorvastatin; Heat-Shock Proteins; HMGB1 Protein; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, LDL; Proprotein Convertase 9; Rabbits; RNA, Small Interfering | 2022 |
Detection of lipid efflux from foam cell models using a label-free infrared method.
Topics: Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cholesterol; Foam Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic | 2022 |
Atorvastatin ameliorated PM
Topics: Animals; Atherosclerosis; Atorvastatin; Interleukin-6; Male; Particulate Matter; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha | 2023 |
Enhancing the biopharmaceutical attributes of atorvastatin calcium using polymeric and lipid-polymer hybrid nanoparticles: An approach for atherosclerosis treatment.
Topics: Animals; Atherosclerosis; Atorvastatin; Biological Availability; Biological Products; Drug Carriers; Drug Liberation; Lipids; Nanoparticles; Particle Size; Polymers; Rats; Rats, Wistar | 2023 |
The effect of lipid-lowering therapies on the pro-inflammatory and anti-inflammatory properties of vascular endothelial cells.
Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Drug Therapy, Combination; Endothelial Cells; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-10; Interleukin-18; Interleukin-23; RNA, Messenger; Rosuvastatin Calcium; Transforming Growth Factor beta | 2023 |
A Practical Statin Recommendation System Based on Real-World Data to Improve LDL-C Management in Secondary Prevention.
Topics: Atherosclerosis; Atorvastatin; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Rosuvastatin Calcium; Secondary Prevention; Treatment Outcome | 2023 |
Effects of Atorvastatin on Bile Acid Metabolism in High-fat Diet-fed ApoE -/- Mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Bile Acids and Salts; Cholesterol; Diet, High-Fat; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Mice; Mice, Knockout, ApoE; RNA, Messenger | 2023 |
Desipramine enhances the stability of atherosclerotic plaque in rabbits monitored with molecular imaging.
Topics: Animals; Atherosclerosis; Atorvastatin; Desipramine; Molecular Imaging; Plaque, Atherosclerotic; Rabbits | 2023 |
Modeling of chitosan modified PLGA atorvastatin-curcumin conjugate (AT-CU) nanoparticles, overcoming the barriers associated with PLGA: An approach for better management of atherosclerosis.
Topics: Animals; Atherosclerosis; Atorvastatin; Chitosan; Copper; Curcumin; Drug Carriers; Glycols; Mice; Nanoparticles; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer | 2023 |
DRP1 knockdown and atorvastatin alleviate ox-LDL-induced vascular endothelial cells injury: DRP1 is a potential target for preventing atherosclerosis.
Topics: Apoptosis; Atherosclerosis; Atorvastatin; Dynamins; Human Umbilical Vein Endothelial Cells; Humans; Lipoproteins, LDL | 2023 |
The appropriateness of the use of statins for the secondary and primary prevention of atherosclerotic cardiovascular disease: a cross-sectional study from Jordan.
Topics: Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cross-Sectional Studies; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Jordan; Primary Prevention; United States | 2023 |
Oxidized dietary lipids induce vascular inflammation and atherogenesis in post-menopausal rats: estradiol and selected antihyperlipidemic drugs restore vascular health in vivo.
Topics: Animals; Atherosclerosis; Atorvastatin; Cholesterol; Diet; Estradiol; Estrogens; Female; Humans; Hypolipidemic Agents; Inflammation; Lipids; Nitric Oxide; Ovariectomy; Postmenopause; Rats; Tumor Necrosis Factor-alpha | 2023 |
The effect of evolocumab alone and in combination with atorvastatin on atherosclerosis progression and TLRs expression.
Topics: Animals; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Interleukin-17; Male; Rabbits; Treatment Outcome | 2023 |
DL-3-n-butylphthalide improves the endothelium-dependent vasodilation in high-fat diet-fed ApoE
Topics: Animals; Apolipoproteins E; Apoptosis; Atherosclerosis; Atorvastatin; Cytokines; Diet, High-Fat; Endothelium; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Ischemic Stroke; Male; Mice; Mice, Knockout; Necroptosis; Vasodilation | 2023 |
Metal-phenolic capsules with ROS scavenging reshape the oxidative microenvironment of atherosclerosis.
Topics: Anti-Inflammatory Agents; Antioxidants; Atherosclerosis; Atorvastatin; Capsules; Humans; Oxidative Stress; Reactive Oxygen Species | 2023 |
A novel circular RNA, circSQSTM1, protects the endothelial function in atherosclerosis.
Topics: Animals; Atherosclerosis; Atorvastatin; Endothelial Cells; In Situ Hybridization, Fluorescence; Inflammation; Mice; RNA, Circular; Sirtuin 1 | 2023 |
Inhibition of EphA2 protects against atherosclerosis by synergizing with statins to mitigate macrophage inflammation.
Topics: Animals; Atherosclerosis; Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Macrophages; Mice; Plaque, Atherosclerotic | 2023 |
Human Lupus Plasma Pro-Atherogenic Effects on Cultured Macrophages Are Not Mitigated by Statin Therapy: A Mechanistic LAPS Substudy.
Topics: Adult; Atherosclerosis; Atorvastatin; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Cholesterol; Disease Progression; Female; Gene Expression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Liver X Receptors; Lupus Erythematosus, Systemic; Macrophages; Male; Mixed Function Oxygenases; Plasma; PPAR gamma; RNA, Messenger | 2019 |
Safety of High-Intensity Statins in the Veteran Population: Atorvastatin 40 to 80 mg Compared With Rosuvastatin 20 to 40 mg.
Topics: Aged; Atherosclerosis; Atorvastatin; Cohort Studies; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Odds Ratio; Retrospective Studies; Rosuvastatin Calcium; Veterans | 2020 |
Atheroprotective effects of methotrexate via the inhibition of YAP/TAZ under disturbed flow.
Topics: Adaptor Proteins, Signal Transducing; Adenylate Kinase; Animals; Apoptosis; Atherosclerosis; Atorvastatin; Cell Nucleus; Gene Silencing; Hemorheology; Human Umbilical Vein Endothelial Cells; Humans; Male; Methotrexate; Mice, Inbred C57BL; Models, Biological; Phosphorylation; Plaque, Atherosclerotic; Trans-Activators; Transcription Factors; Transcriptional Coactivator with PDZ-Binding Motif Proteins; YAP-Signaling Proteins | 2019 |
Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence.
Topics: Aged; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Recurrence; Registries; Retrospective Studies; Rosuvastatin Calcium; Secondary Prevention; Spain; Therapeutic Equivalency | 2019 |
Atorvastatin inhibits pyroptosis through the lncRNA NEXN-AS1/NEXN pathway in human vascular endothelial cells.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blotting, Western; Cells, Cultured; Endothelial Cells; Gene Expression Regulation; Humans; Inflammasomes; Microfilament Proteins; Pyroptosis; RNA, Long Noncoding; Signal Transduction | 2020 |
Oxidized Low Density Lipoprotein-Induced Atherogenic Response of Human Umbilical Vascular Endothelial Cells (HUVECs) was Protected by Atorvastatin by Regulating miR-26a-5p/Phosphatase and Tensin Homolog (PTEN).
Topics: Apoptosis; Atherosclerosis; Atorvastatin; Cell Survival; Gene Expression Regulation; Human Umbilical Vein Endothelial Cells; Humans; Lipoproteins, LDL; MicroRNAs; Oxidative Stress; PTEN Phosphohydrolase | 2019 |
LOX-1, the Common Therapeutic Target in Hypercholesterolemia: A New Perspective of Antiatherosclerotic Action of Aegeline.
Topics: Amides; Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cell Line; Diet, High-Fat; Disease Models, Animal; Humans; Hypercholesterolemia; Lipoproteins, LDL; Macrophages; Male; Mice; Molecular Targeted Therapy; Rats; Rats, Wistar; Scavenger Receptors, Class E | 2019 |
ANGPTL3, PCSK9, and statin therapy drive remarkable reductions in hyperlipidemia and atherosclerosis in a mouse model.
Topics: Angiopoietin-Like Protein 3; Angiopoietin-like Proteins; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atherosclerosis; Atorvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Mice; Proprotein Convertase 9 | 2020 |
Statins Disrupt Macrophage Rac1 Regulation Leading to Increased Atherosclerotic Plaque Calcification.
Topics: Aged; Animals; Atherosclerosis; Atorvastatin; Cells, Cultured; Disease Models, Animal; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1beta; Macrophages; Male; Mice, Knockout, ApoE; Neuropeptides; Plaque, Atherosclerotic; Prenylation; rac1 GTP-Binding Protein; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Retrospective Studies; rho Guanine Nucleotide Dissociation Inhibitor alpha; Signal Transduction; Vascular Calcification | 2020 |
Myriocin and d-PDMP ameliorate atherosclerosis in ApoE-/- mice via reducing lipid uptake and vascular inflammation.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins E; Atherosclerosis; Atorvastatin; Biological Transport; Ceramides; Fatty Acids, Monounsaturated; Glycosphingolipids; Immunosuppressive Agents; Lipid Metabolism; Lipids; Mice, Inbred C57BL; Mice, Knockout; Morpholines; Plaque, Atherosclerotic; Vasculitis | 2020 |
[Regulatory effect of Di'ao Xinxuekang on TLR4/MyD88/NF-κB signaling pathway in atherosclerotic rats].
Topics: Animals; Aorta; Atherosclerosis; Atorvastatin; Drugs, Chinese Herbal; Interleukin-6; Interleukin-8; Lipids; Myeloid Differentiation Factor 88; Random Allocation; Rats; Rats, Sprague-Dawley; Signal Transduction; Toll-Like Receptor 4; Transcription Factor RelA; Tumor Necrosis Factor-alpha | 2020 |
Macrophage-Enriched lncRNA RAPIA: A Novel Therapeutic Target for Atherosclerosis.
Topics: Animals; Apoptosis; Atherosclerosis; Atorvastatin; Cell Proliferation; Disease Progression; Forkhead Box Protein O1; Gene Expression; Humans; Integrin beta1; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout, ApoE; MicroRNAs; Promoter Regions, Genetic; RAW 264.7 Cells; RNA, Long Noncoding | 2020 |
Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines.
Topics: Animals; Aorta; Atherosclerosis; Atorvastatin; Biomimetic Materials; Cell Membrane; Cytokines; Drug Delivery Systems; Drug Liberation; Female; Macrophages; Mice; Nanoparticles; RAW 264.7 Cells; Reactive Oxygen Species; Treatment Outcome | 2020 |
Variability in blood lipids affects the neutrophil to lymphocyte ratio in patients undergoing elective percutaneous coronary intervention: a retrospective study.
Topics: Aged; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipid Metabolism; Lipids; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Risk Factors | 2020 |
[Preprocedural high - sensitivity C-reactive protein (hsCRP) decrease during intensive atorvastatin therapy: the presumable impact on atherosclerosis progression after coronary stenting].
Topics: Atherosclerosis; Atorvastatin; C-Reactive Protein; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Treatment Outcome | 2019 |
Effect of cholesterol re-supplementation and atorvastatin on plaque composition in the thoracic aorta of New Zealand white rabbits.
Topics: Animals; Aorta, Thoracic; Aortic Diseases; Atherosclerosis; Atorvastatin; Cholesterol, Dietary; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Rabbits; Time Factors | 2020 |
Combined application of rapamycin and atorvastatin improves lipid metabolism in apolipoprotein E-deficient mice with chronic kidney disease.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cytokines; Disease Models, Animal; Female; Lipid Metabolism; Mice; Mice, Knockout; Renal Insufficiency, Chronic; Sirolimus | 2021 |
Atorvastatin Enhances Foam Cell Lipophagy and Promotes Cholesterol Efflux Through the AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Pathway.
Topics: AMP-Activated Protein Kinases; Atherosclerosis; Atorvastatin; Autophagy; Autophagy-Related Proteins; Cholesterol; Foam Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Droplets; Phosphorylation; Signal Transduction; THP-1 Cells; TOR Serine-Threonine Kinases | 2021 |
The effects of melatonin against atherosclerosis-induced endothelial dysfunction and inflammation in hypercholesterolemic rats.
Topics: Animals; Atherosclerosis; Atorvastatin; Hypercholesterolemia; Hyperlipidemias; Inflammation; Melatonin; Nicotinamide Phosphoribosyltransferase; Nitric Oxide; Rats | 2023 |
Effects of Atorvastatin Combined with Nano-Selenium on Blood Lipids and Oxidative Stress in Atherosclerotic Rats.
Topics: Animals; Atherosclerosis; Atorvastatin; Lipids; Oxidative Stress; Pharmaceutical Preparations; Rats; Selenium | 2021 |
Inhibition of macrophage proliferation dominates plaque regression in response to cholesterol lowering.
Topics: Animals; Apolipoprotein E3; Atherosclerosis; Atorvastatin; Biomarkers; Cell Proliferation; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Diet, Fat-Restricted; Disease Models, Animal; Down-Regulation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Mice, Inbred C57BL; Mice, Knockout, ApoE; Plaque, Atherosclerotic; Receptors, LDL | 2020 |
Western and heart healthy dietary patterns differentially affect the expression of genes associated with lipid metabolism, interferon signaling and inflammation in the jejunum of Ossabaw pigs.
Topics: Animals; Atherosclerosis; Atorvastatin; Cardiometabolic Risk Factors; Coronary Artery Disease; Delta-5 Fatty Acid Desaturase; Diet, Healthy; Diet, Western; Feeding Behavior; Female; Gene Expression; Heart; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interferons; Intestinal Mucosa; Jejunum; Lipid Metabolism; Male; Swine; Tumor Necrosis Factor-alpha | 2021 |
Colon transcriptome is modified by a dietary pattern/atorvastatin interaction in the Ossabaw pig.
Topics: Animals; Atherosclerosis; Atorvastatin; Cholesterol, Dietary; Colon; Coronary Artery Disease; Diet; Diet, Healthy; Diet, High-Fat; Diet, Western; Dietary Fats; Feeding Behavior; Female; Gene Expression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Swine; Transcriptome | 2021 |
Atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease.
Topics: Aged; Anti-Inflammatory Agents; Aorta; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; Female; Fluorodeoxyglucose F18; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Plaque, Atherosclerotic; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Renal Insufficiency, Chronic; Risk Factors | 2021 |
Escalation of liPid-lOwering therapy in patientS wiTh vascular disease receiving HIGH-intensity statins: the retrospective POST-HIGH study.
Topics: Aged; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Republic of Korea; Retrospective Studies | 2021 |
Hsa_circ_0004831 downregulation is partially responsible for atorvastatinalleviated human umbilical vein endothelial cell injuries induced by ox-LDL through targeting the miR-182-5p/CXCL12 axis.
Topics: Anti-Inflammatory Agents; Antioxidants; Apoptosis; Atherosclerosis; Atorvastatin; Cell Cycle; Cells, Cultured; Chemokine CXCL12; Down-Regulation; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; MicroRNAs; Oxidative Stress; RNA, Circular; Signal Transduction | 2021 |
Combination of atorvastatin or hydrochlorothiazide/amlodipine with
Topics: Amlodipine; Atherosclerosis; Atorvastatin; Drugs, Chinese Herbal; Humans; Hydrochlorothiazide; Hyperlipidemias; Hypertension; Pueraria; Salvia miltiorrhiza | 2021 |
Effect of Nigella sativa, atorvastatin, or L-Carnitine on high fat diet-induced obesity in adult male Albino rats.
Topics: Animals; Anti-Obesity Agents; Atherosclerosis; Atorvastatin; Blood Glucose; Body Weight; Carnitine; Diet, High-Fat; Fatty Liver; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nigella sativa; Obesity; Plant Extracts; Rats; Rats, Wistar | 2021 |
Effects of Torcetrapib and Statin Treatment on ApoC-III and Apoprotein-Defined Lipoprotein Subclasses (from the ILLUMINATE Trial).
Topics: Anticholesteremic Agents; Apolipoprotein C-III; Apoproteins; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Male; Middle Aged; Quinolines; Retrospective Studies; Treatment Outcome | 2017 |
Effects of atorvastatin and diet interventions on atherosclerotic plaque inflammation and [
Topics: Animal Feed; Animals; Aortic Diseases; Apolipoprotein B-100; Atherosclerosis; Atorvastatin; Diet, Fat-Restricted; Diet, High-Fat; Disease Models, Animal; Female; Fluorodeoxyglucose F18; Genetic Predisposition to Disease; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Mice, Knockout; Phenotype; Plaque, Atherosclerotic; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Receptors, LDL; Time Factors | 2017 |
Preparation and characterisation of atorvastatin and curcumin-loaded chitosan nanoformulations for oral delivery in atherosclerosis.
Topics: Administration, Oral; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Chitosan; Curcumin; Delayed-Action Preparations; Diffusion; Drug Combinations; Drug Compounding; Humans; Nanocapsules; Particle Size | 2017 |
Combined use of metformin and atorvastatin attenuates atherosclerosis in rabbits fed a high-cholesterol diet.
Topics: Animals; Atherosclerosis; Atorvastatin; Biomarkers; Biopsy; Cholesterol; Diet, High-Fat; Disease Models, Animal; Gene Expression; Immunohistochemistry; Lipid Metabolism; Male; Metformin; Plaque, Atherosclerotic; Rabbits | 2017 |
Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Cohort Studies; Computer Simulation; Databases, Factual; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Monte Carlo Method; Patient Care Planning; PCSK9 Inhibitors | 2017 |
Therapeutic Effect and Mechanism of Action of Abnormal Savda Munziq in Development of Degenerative Atherosclerotic Aortic Valve Disease.
Topics: Animals; Aortic Valve; Aortic Valve Stenosis; Atherosclerosis; Atorvastatin; Bicuspid Aortic Valve Disease; Calcinosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diet, High-Fat; Drugs, Chinese Herbal; Heart Defects, Congenital; Heart Valve Diseases; Male; Medicine, Traditional; Plant Extracts; Rabbits; Triglycerides | 2017 |
Anti-atherosclerotic effect of Longxuetongluo Capsule in high cholesterol diet induced atherosclerosis model rats.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Aorta; Atherosclerosis; Atorvastatin; Diet, High-Fat; Disease Models, Animal; Drugs, Chinese Herbal; Hypercholesterolemia; Inflammation; Lipid Metabolism; Lipids; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; NF-kappa B; Plaque, Atherosclerotic; Rats; Rats, Sprague-Dawley | 2018 |
Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis.
Topics: Adipose Tissue; Adipose Tissue, Brown; Animals; Atherosclerosis; Atorvastatin; Calorimetry, Indirect; Cholesterol Ester Transfer Proteins; Female; Gene Expression Profiling; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Lipids; Lipoproteins; Liver; Mice; Mice, Knockout, ApoE; Proprotein Convertase 9; Receptors, Adrenergic, beta-3; Triglycerides | 2017 |
Target achievement with maximal statin-based lipid-lowering therapy in Korean patients with familial hypercholesterolemia: A study supported by the Korean Society of Lipid and Atherosclerosis.
Topics: Administration, Oral; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Biomarkers; Cholesterol; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Incidence; Male; Middle Aged; Republic of Korea; Rosuvastatin Calcium; Societies, Medical; Treatment Outcome | 2017 |
Therapeutic effects of fibroblast growth factor‑21 against atherosclerosis via the NF‑κB pathway.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Endothelial Cells; Female; Fibroblast Growth Factors; Lipids; NF-kappa B; Rats, Wistar; Signal Transduction | 2018 |
Celosins inhibit atherosclerosis in ApoE
Topics: Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Autophagy; Cells, Cultured; Celosia; Diet, High-Fat; Dose-Response Relationship, Drug; Macrophages, Peritoneal; Mice; Mice, Knockout; Molecular Structure; Plant Extracts; Saponins | 2018 |
Atorvastatin Reduces Plasma Inflammatory and Oxidant Biomarkers in Patients With Risk of Atherosclerotic Cardiovascular Disease.
Topics: Adult; Aged; Atherosclerosis; Atorvastatin; C-Reactive Protein; Dose-Response Relationship, Drug; Endothelin-1; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Middle Aged; Oxidants; Oxidative Stress; Peroxidase; Prospective Studies; Risk Factors; Superoxide Dismutase | 2018 |
Sex disparity in the management and outcomes of dyslipidemia of diabetic patients in the Arabian Gulf: findings from the CEPHEUS study.
Topics: Adult; Aged; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus; Dyslipidemias; Female; Humans; Hypolipidemic Agents; Male; Middle Aged; Middle East; Rosuvastatin Calcium; Sex Characteristics; Simvastatin | 2018 |
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Coronary Disease; Drug Therapy, Combination; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Male; Maximum Tolerated Dose; Middle Aged; PCSK9 Inhibitors; Peripheral Arterial Disease; Risk; Rosuvastatin Calcium; Simvastatin; Stroke; Treatment Outcome | 2018 |
Atorvastatin improves plaque stability in diabetic atherosclerosis through the RAGE pathway.
Topics: Animals; Atherosclerosis; Atorvastatin; Diabetes Mellitus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidative Stress; Plaque, Atherosclerotic; Receptor for Advanced Glycation End Products | 2018 |
[The REVEAL study].
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Oxazolidinones; Randomized Controlled Trials as Topic; Treatment Outcome | 2018 |
The Ossabaw Pig Is a Suitable Translational Model to Evaluate Dietary Patterns and Coronary Artery Disease Risk.
Topics: Animals; Atherosclerosis; Atorvastatin; Cholesterol; Coronary Artery Disease; Diet, Healthy; Diet, Western; Dietary Fats; Disease Models, Animal; Dyslipidemias; Energy Intake; Fatty Acids; Feeding Behavior; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Risk Factors; Swine; Triglycerides | 2018 |
Protective effect of atorvastatin meditated by HMGCR gene on diabetic rats with atherosclerosis: An in vivo and in vitro study.
Topics: Animals; Atherosclerosis; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Experimental; Fatty Acid Synthase, Type I; Female; Hydroxymethylglutaryl CoA Reductases; Insulin; Male; Protective Agents; Rats; Rats, Wistar; Receptors, LDL; RNA, Messenger; Triglycerides | 2018 |
All-trans retinoic acid effectively reduces atheroma plaque size in a rabbit model of high-fat-induced atherosclerosis.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Diet, High-Fat; Hypercholesterolemia; Lipids; Plaque, Atherosclerotic; Rabbits; Random Allocation; Tretinoin; Tunica Intima | 2018 |
Atheroprone flow enhances the endothelial-to-mesenchymal transition.
Topics: AMP-Activated Protein Kinases; Animals; Antigens, CD; Atherosclerosis; Atorvastatin; Cadherins; Cells, Cultured; DNA Methylation; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Gene Expression Regulation; Human Umbilical Vein Endothelial Cells; Humans; Metformin; Mice, Inbred C57BL; Platelet Endothelial Cell Adhesion Molecule-1; Promoter Regions, Genetic; Pulsatile Flow; Regional Blood Flow; S100 Calcium-Binding Protein A4; Sirtuin 1; Stress, Mechanical; Time Factors; Vimentin; von Willebrand Factor | 2018 |
A Thorny Finding: Unexpected Acanthocytosis in an Elderly Patient.
Topics: Abetalipoproteinemia; Aged; Atherosclerosis; Atorvastatin; Diabetes Complications; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Parkinson Disease | 2018 |
Effect of Combined Use of Astragaloside IV (AsIV) and Atorvastatin (AV) on Expression of PPAR-γ and Inflammation-Associated Cytokines in Atherosclerosis Rats.
Topics: Animals; Atherosclerosis; Atorvastatin; China; Cytokines; Disease Models, Animal; Drug Therapy, Combination; Inflammation; Interleukin-18; Interleukin-6; Lipoproteins, HDL; Lipoproteins, LDL; Male; PPAR gamma; Rats; Rats, Sprague-Dawley; Saponins; Signal Transduction; Triterpenes; Tumor Necrosis Factor-alpha | 2018 |
Simultaneous LC-MS/MS analysis of simvastatin, atorvastatin, rosuvastatin and their active metabolites for plasma samples of obese patients underwent gastric bypass surgery.
Topics: Adult; Atherosclerosis; Atorvastatin; Calibration; Chromatography, High Pressure Liquid; Female; Gastric Bypass; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Obesity; Postoperative Period; Preoperative Period; Reproducibility of Results; Rosuvastatin Calcium; Simvastatin; Tandem Mass Spectrometry | 2019 |
Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention: Results from a large single-center prospective registry.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angina, Unstable; Atherosclerosis; Atorvastatin; Drug Prescriptions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Practice Guidelines as Topic; Prospective Studies; Registries; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; ST Elevation Myocardial Infarction; Tertiary Care Centers; Time Factors | 2019 |
Onset timing of statin-induced musculoskeletal adverse events and concomitant drug-associated shift in onset timing of MAEs.
Topics: Adverse Drug Reaction Reporting Systems; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Drug Interactions; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Musculoskeletal Diseases; Rosuvastatin Calcium; Simvastatin; Time Factors; United States; United States Food and Drug Administration | 2018 |
Efficacy comparison of rosuvastatin and atorvastatin in the treatment of atherosclerosis and drug safety analysis.
Topics: Adult; Aged; Atherosclerosis; Atorvastatin; Carotid Arteries; Female; Humans; Male; Middle Aged; Plaque, Atherosclerotic; Rosuvastatin Calcium | 2018 |
Fufang-Zhenzhu-Tiaozhi Capsule reduces restenosis via the downregulation of NF-kappaB and inflammatory factors in rabbits.
Topics: Animals; Aorta, Abdominal; Atherosclerosis; Atorvastatin; C-Reactive Protein; Chemokine CCL2; Coronary Restenosis; Diet, High-Fat; Disease Models, Animal; Drugs, Chinese Herbal; Endothelium; Gene Expression Regulation; Humans; Inflammation; Interleukin-1; Interleukin-12; Interleukin-6; Interleukin-8; NF-kappa B; Rabbits; Tumor Necrosis Factor-alpha | 2018 |
Atorvastatin downregulates HSP22 expression in an atherosclerotic model in vitro and in vivo.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cell Cycle Checkpoints; Diet, High-Fat; Down-Regulation; Heat-Shock Proteins; HSP20 Heat-Shock Proteins; Human Umbilical Vein Endothelial Cells; Humans; Lipoproteins, LDL; Male; Mice; Molecular Chaperones; Muscle Proteins; Nitric Oxide Synthase Type III; p38 Mitogen-Activated Protein Kinases; Protein Serine-Threonine Kinases | 2019 |
Effects of atorvastatin and/or probucol on recovery of atherosclerosis in high-fat-diet-fed apolipoprotein E-deficient mice.
Topics: Animals; Antioxidants; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cholesterol; Cytokines; Diet, High-Fat; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Inflammation; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Probucol | 2019 |
The effects of pro- and anti-atherosclerotic factors on intracellular nucleotide concentration in murine endothelial cells.
Topics: Adenosine Triphosphate; Animals; Atherosclerosis; Atorvastatin; Blood Vessels; Cell Line; Cytokines; Docosahexaenoic Acids; Endothelial Cells; Fatty Acids, Unsaturated; Kaempferols; Linoleic Acid; Mice; NAD; Nucleotides; Palmitic Acid; Pyridines | 2018 |
Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects.
Topics: Atherosclerosis; Atorvastatin; Cytochrome P-450 CYP3A; DNA; Female; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; India; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Pharmacogenetics; Polymerase Chain Reaction; Polymorphism, Genetic; Rosuvastatin Calcium | 2018 |
Synergistic effects of liposomes encapsulating atorvastatin calcium and curcumin and targeting dysfunctional endothelial cells in reducing atherosclerosis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cell Death; Cell Survival; Chemokine CCL2; Curcumin; Drug Synergism; E-Selectin; Endothelial Cells; Humans; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-6; Ligands; Lipids; Liposomes; Mice, Knockout; Particle Size; Static Electricity | 2019 |
Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.
Topics: Algorithms; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Drug Tolerance; Ezetimibe; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Retrospective Studies | 2019 |
Statins' Withdrawal Induces Atherosclerotic Plaque Destabilization in Animal Model-A "Rebound" Stimulation of Inflammation.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Aortic Diseases; Atherosclerosis; Atorvastatin; Collagen; Disease Models, Animal; Disease Progression; Drug Administration Schedule; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Mice, Knockout, ApoE; Plaque, Atherosclerotic; Rupture, Spontaneous; Signal Transduction; Time Factors | 2019 |
A Western-type dietary pattern and atorvastatin induce epicardial adipose tissue interferon signaling in the Ossabaw pig.
Topics: Adipose Tissue; Animals; Atherosclerosis; Atorvastatin; Diet, Western; Female; Food-Drug Interactions; Gene Expression Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferons; Male; Pericardium; Swine; Swine, Miniature | 2019 |
Contribution of aorta glycosaminoglycans and PCSK9 to hyperlipidemia in experimental rabbits: the role of 10-dehdrogingerdione as effective modulator.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Atherosclerosis; Atorvastatin; Cholesterol; Glycosaminoglycans; Guaiacol; Hyperlipidemias; Lipids; Male; Proprotein Convertase 9; Rabbits; Tumor Necrosis Factor-alpha | 2019 |
Evacetrapib reduces preβ-1 HDL in patients with atherosclerotic cardiovascular disease or diabetes.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Benzodiazepines; Cardiovascular Diseases; Diabetes Mellitus; High-Density Lipoproteins, Pre-beta; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2019 |
Integrated proteomics and metabolomics analysis reveals differential lipid metabolism in human umbilical vein endothelial cells under high and low shear stress.
Topics: Atherosclerosis; Atorvastatin; Cells, Cultured; Cholesterol; Glycosylation; Hemodynamics; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipidomics; Mechanotransduction, Cellular; Phenotype; Plaque, Atherosclerotic; Protein Processing, Post-Translational; Proteomics; Receptors, LDL; Regional Blood Flow; Stress, Mechanical | 2019 |
An in vitro model of foam cell formation induced by a stretchable microfluidic device.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Coculture Techniques; Foam Cells; Human Umbilical Vein Endothelial Cells; Humans; Lab-On-A-Chip Devices; Lipoproteins, LDL; Microfluidics; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Stress, Mechanical | 2019 |
Membrane-permeabilized sonodynamic therapy enhances drug delivery into macrophages.
Topics: Atherosclerosis; Atorvastatin; Calcium; Cell Line; Cell Membrane; Cell Membrane Permeability; Cell Survival; Cholesterol; Foam Cells; Humans; Lipid Droplets; Macrophages; Membrane Potential, Mitochondrial; Plaque, Atherosclerotic; Protoporphyrins; Reactive Oxygen Species; THP-1 Cells; Ultrasonic Therapy | 2019 |
Atorvastatin Blocks Advanced Glycation End Products Induced Reduction in Macrophage Cholesterol Efflux Mediated With ATP-Binding Cassette Transporters G 1.
Topics: Animals; Atherosclerosis; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 1; Cholesterol; Disease Models, Animal; Down-Regulation; Glycation End Products, Advanced; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages, Peritoneal; Male; Mice, Inbred C57BL; Mice, Knockout, ApoE; Receptor for Advanced Glycation End Products; THP-1 Cells | 2019 |
Nitric oxide-donating statins upgrade the benefits of lipid-lowering in vascular inflammation by desensitizing neutrophil activation: editorial to: "Nitric oxide-donating atorvastatin attenuates neutrophil recruitment during vascular inflammation independ
Topics: Animals; Atherosclerosis; Atorvastatin; Cholesterol; Heptanoic Acids; Humans; Male; Neutrophil Infiltration; Nitric Oxide Donors; Pyrroles | 2013 |
Multiple statistical methods for assessing differential gene expression in microarray data of diabetic model rats to predict the molecular mechanism of atorvastatin on anti-atherogenesis.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Data Interpretation, Statistical; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Gene Expression Profiling; Heptanoic Acids; Male; Microarray Analysis; Prognosis; Pyrroles; Rats; Rats, Sprague-Dawley; Rats, Wistar; Streptozocin; Treatment Outcome | 2013 |
Monitoring plaque inflammation in atherosclerotic rabbits with an iron oxide (P904) and (18)F-FDG using a combined PET/MR scanner.
Topics: Animals; Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Atorvastatin; Contrast Media; Dextrans; Disease Models, Animal; Disease Progression; Fluorodeoxyglucose F18; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Magnetic Resonance Imaging; Magnetite Nanoparticles; Plaque, Atherosclerotic; Positron-Emission Tomography; Predictive Value of Tests; Pyrroles; Rabbits; Radiography; Radiopharmaceuticals; Time Factors | 2013 |
Atorvastatin inhibits the 5-lipoxygenase pathway and expression of CCL3 to alleviate atherosclerotic lesions in atherosclerotic ApoE knockout mice.
Topics: Animals; Anticholesteremic Agents; Aorta; Apolipoproteins E; Arachidonate 5-Lipoxygenase; Atherosclerosis; Atorvastatin; Chemokine CCL3; Cholesterol, Dietary; Down-Regulation; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukotrienes; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Pyrroles; Random Allocation; Signal Transduction | 2013 |
Osteoarthritis development is induced by increased dietary cholesterol and can be inhibited by atorvastatin in APOE*3Leiden.CETP mice--a translational model for atherosclerosis.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein E3; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, Dietary; Disease Models, Animal; Heptanoic Acids; Humans; Hypercholesterolemia; Mice; Mice, Transgenic; Osteoarthritis; Pyrroles | 2014 |
[Impacts of atovastatin and tinidazole on cardiac muscle inflammation factors of tumor necrosis factor-α, interleukin-1 and metalloproteinase-2 of experimental rabbits with atherosclerosis and periodontitis].
Topics: Animals; Atherosclerosis; Atorvastatin; Heptanoic Acids; Interleukin-1; Male; Matrix Metalloproteinase 2; Periodontitis; Pyrroles; Rabbits; Tinidazole; Tumor Necrosis Factor-alpha | 2013 |
Effect of minocycline on carotid atherosclerotic plaques.
Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Atorvastatin; Basigin; Carotid Artery, Common; Cholesterol; Cholesterol, LDL; Heptanoic Acids; Male; Matrix Metalloproteinase 9; Minocycline; Plaque, Atherosclerotic; Pyrroles; Rabbits | 2013 |
Effect of atorvastatin on expression of TLR4 and NF-κB p65 in atherosclerotic rabbits.
Topics: Animals; Anticholesteremic Agents; Aorta; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Disease Models, Animal; Gene Expression; Heptanoic Acids; Histocytochemistry; Male; Pyrroles; Rabbits; Random Allocation; Toll-Like Receptor 4; Transcription Factor RelA | 2013 |
In vivo evaluation of atherosclerotic plaque inflammation and of anti-inflammatory effects of statins by 18F-fluorodeoxyglucose positron emission tomography.
Topics: Aorta, Thoracic; Atherosclerosis; Atorvastatin; Carotid Arteries; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Plaque, Atherosclerotic; Pyrroles; Radionuclide Imaging | 2013 |
Effect of atorvastatin on atherosclerotic plaque formation and platelet activation in hypercholesterolemic rats.
Topics: Animals; Aorta; Aortic Diseases; Atherosclerosis; Atorvastatin; Biomarkers; CD40 Antigens; CD40 Ligand; Cholesterol, Dietary; Disease Models, Animal; Disease Progression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-6; Lipids; Male; P-Selectin; Plaque, Atherosclerotic; Platelet Activation; Platelet Factor 4; Pyrroles; Rats; Rats, Wistar | 2013 |
STOMPing forward: statins, muscle complaints and CK.
Topics: Atherosclerosis; Atorvastatin; Creatine Kinase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle Weakness; Muscle, Skeletal; Muscles; Muscular Diseases; Myalgia; Pyrroles; Randomized Controlled Trials as Topic | 2013 |
Effect of atorvastatin on low-density lipoprotein subpopulations and comparison between indicators of plasma atherogenicity: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Apolipoproteins B; Atherosclerosis; Atorvastatin; Biomarkers; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemias; Lipoproteins, LDL; Male; Middle Aged; Pilot Projects; Pyrroles; Time Factors; Treatment Outcome; Triglycerides | 2014 |
Inhibitory effect of co-administration of atorvastatin and endothelin-1 receptor antagonist on the progression of atherosclerosis in rabbit.
Topics: Animals; Aorta, Abdominal; Atherosclerosis; Atorvastatin; Diet, High-Fat; Disease Models, Animal; Disease Progression; Down-Regulation; Drug Synergism; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Endothelin-1; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iliac Artery; Inflammation Mediators; Lipids; Male; Matrix Metalloproteinase 9; NF-kappa B; Phenylpropionates; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rabbits; RNA, Messenger | 2014 |
Near-infrared fluorescence imaging of murine atherosclerosis using an oxidized low density lipoprotein-targeted fluorochrome.
Topics: Animals; Antibodies; Aorta; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cell Line; Cholesterol, Dietary; Disease Models, Animal; Disease Progression; Feasibility Studies; Fluorescent Dyes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isothiocyanates; Lipoproteins, LDL; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Optical Imaging; Plaque, Atherosclerotic; Pyrroles; Time Factors | 2014 |
Probucol inhibits the initiation of atherosclerosis in cholesterol-fed rabbits.
Topics: Animals; Anticholesteremic Agents; Aorta; Atherosclerosis; Atorvastatin; Cell Adhesion; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dietary Fats; Endothelial Cells; Heptanoic Acids; Hypercholesterolemia; Macrophages; Male; Monocytes; Plaque, Atherosclerotic; Probucol; Pyrroles; Rabbits; Triglycerides; Tunica Intima | 2013 |
The thyroid receptor modulator KB3495 reduces atherosclerosis independently of total cholesterol in the circulation in ApoE deficient mice.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins B; Apolipoproteins E; Atherosclerosis; Atorvastatin; Bile Acids and Salts; Biological Transport; Cytokines; Disease Models, Animal; Drug Synergism; Feces; Heptanoic Acids; Male; Mice; Mice, Knockout; Molecular Mimicry; Plaque, Atherosclerotic; Pyrroles; Thyroid Hormones | 2013 |
Atorvastatin suppresses Toll-like receptor 4 expression and NF-κB activation in rabbit atherosclerotic plaques.
Topics: Animals; Atherosclerosis; Atorvastatin; Diet, High-Fat; Gene Expression Regulation; Heptanoic Acids; NF-kappa B; Plaque, Atherosclerotic; Pyrroles; Rabbits; RNA, Messenger; Signal Transduction; Toll-Like Receptor 4 | 2014 |
Comparison of the effects of escitalopram and atorvastatin on diet-induced atherosclerosis in rats.
Topics: Animals; Aorta, Abdominal; Atherosclerosis; Atorvastatin; Body Weight; Citalopram; Diet, High-Fat; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Pyrroles; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Vascular Cell Adhesion Molecule-1 | 2014 |
Characterization of the pharmaceutical effect of drugs on atherosclerotic lesions in vivo using integrated fluorescence imaging and Raman spectral measurements.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Azetidines; Blood Vessels; Ezetimibe; Heptanoic Acids; Hypercholesterolemia; Lipid Metabolism; Lipids; Microscopy, Confocal; Pyrroles; Spectrum Analysis, Raman; Zebrafish | 2014 |
Statin treatment is associated with reduction in serum levels of receptor activator of NF-κB ligand and neutrophil activation in patients with severe carotid stenosis.
Topics: Aged; Atherosclerosis; Atorvastatin; Carotid Stenosis; Cohort Studies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinase 9; Middle Aged; Neutrophil Activation; Neutrophils; NF-kappa B; Osteopontin; Osteoprotegerin; Pyrimidines; Pyrroles; RANK Ligand; Risk Factors; RNA, Messenger; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2014 |
[Lipid-lowering therapy and patient adherence in the MULTI GAP 2013 trial].
Topics: Adult; Aged; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Databases, Factual; Drug Prescriptions; Drug Therapy, Combination; Female; Fluorobenzenes; Guideline Adherence; Heptanoic Acids; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insurance, Health; Male; Middle Aged; Patient Compliance; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Surveys and Questionnaires; Treatment Outcome | 2014 |
Berberine combined with atorvastatin downregulates LOX‑1 expression through the ET‑1 receptor in monocyte/macrophages.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Berberine; Body Weight; Cells, Cultured; Cholesterol; Diet, High-Fat; Dietary Fats; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation; Heptanoic Acids; Macrophages; Male; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; RNA, Small Interfering; Scavenger Receptors, Class E; Signal Transduction; Triglycerides | 2014 |
Impact of serum high mobility group box 1 and soluble receptor for advanced glycation end-products on subclinical atherosclerosis in patients with granulomatosis with polyangiitis.
Topics: Atherosclerosis; Atorvastatin; Female; Granulomatosis with Polyangiitis; Heptanoic Acids; HMGB1 Protein; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prednisolone; Pyrroles; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Solubility | 2014 |
Statin-induced impairment of monocyte migration is gender-related.
Topics: Atherosclerosis; Atorvastatin; Cell Movement; Female; Healthy Volunteers; Heptanoic Acids; Humans; Inflammation; Lipopolysaccharides; Male; Monocytes; Pyrroles; Sex Characteristics; Simvastatin; Tumor Necrosis Factor-alpha | 2014 |
Add-on effect of probucol in atherosclerotic, cholesterol-fed rabbits treated with atorvastatin.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Atherosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol; Drug Synergism; Heptanoic Acids; Probucol; Pyrroles; Rabbits | 2014 |
Effectiveness of combination therapy of atorvastatin and non lipid-modifying tanshinone IIA from Danshen in a mouse model of atherosclerosis.
Topics: Abietanes; Animals; Atherosclerosis; Atorvastatin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drugs, Chinese Herbal; Heptanoic Acids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyrroles; Salvia miltiorrhiza; Treatment Outcome | 2014 |
The roles of nitric oxide and hydrogen sulfide in the anti-atherosclerotic effect of atorvastatin.
Topics: Alkynes; Animals; Aorta, Thoracic; Atherosclerosis; Atorvastatin; Diet, High-Fat; Glycine; Heptanoic Acids; Hydrogen Sulfide; NG-Nitroarginine Methyl Ester; Nitric Oxide; Pyrroles; Rats, Sprague-Dawley | 2015 |
Effect of beta-3 adrenoceptor stimulation on the levels of ApoA-I, PPARα, and PPARγ in apolipoprotein E-deficient mice.
Topics: Adrenergic beta-3 Receptor Agonists; Adrenergic beta-3 Receptor Antagonists; Animals; Apolipoprotein A-I; Apolipoproteins E; Atherosclerosis; Atorvastatin; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Heptanoic Acids; Lipids; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; PPAR alpha; PPAR gamma; Pyrroles; Real-Time Polymerase Chain Reaction; Receptors, Adrenergic, beta-3; RNA, Messenger | 2014 |
The anti-atherogenic effects of berberine on foam cell formation are mediated through the upregulation of sirtuin 1.
Topics: Adenylate Kinase; Atherosclerosis; Atorvastatin; Berberine; Cholesterol; Foam Cells; Heptanoic Acids; Humans; Lipoproteins, LDL; Macrophages; PPAR gamma; Pyrroles; Sirtuin 1; Up-Regulation | 2014 |
Demonstration of an add-on effect of probucol and cilostazol on the statin-induced anti-atherogenic effects.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cilostazol; Drug Therapy, Combination; Heptanoic Acids; Hypercholesterolemia; Immunohistochemistry; Lipids; Probucol; Pyrroles; Rabbits; Tetrazoles | 2014 |
Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet.
Topics: Animals; Apolipoprotein A-I; Atherosclerosis; Atorvastatin; ATP Binding Cassette Transporter 1; Biological Transport; Cell Line; Cholesterol Esters; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, VLDL; Diet, High-Fat; Disease Models, Animal; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2014 |
Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Disease Progression; Drug Combinations; Female; Heptanoic Acids; Mice, Transgenic; Oxazolidinones; Pyrroles; Serum Amyloid A Protein | 2015 |
99mTc-cAbVCAM1-5 imaging is a sensitive and reproducible tool for the detection of inflamed atherosclerotic lesions in mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Female; Heptanoic Acids; Humans; Immunoglobulin Fragments; Immunohistochemistry; Inflammation; Mice; Multimodal Imaging; Pyrroles; Reference Values; Reproducibility of Results; Technetium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Vascular Cell Adhesion Molecule-1 | 2014 |
Insights into the antiatherogenic molecular mechanisms of andrographolide against Porphyromonas gingivalis-induced atherosclerosis in rabbits.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Atherosclerosis; Atorvastatin; Disease Models, Animal; Diterpenes; Dose-Response Relationship, Drug; Heptanoic Acids; Intercellular Adhesion Molecule-1; Lipid Peroxidation; Male; Plaque, Atherosclerotic; Porphyromonas gingivalis; Pyrroles; Rabbits; Vascular Cell Adhesion Molecule-1 | 2014 |
[Proaterogenic metabolic disorders in patients with chronic kidney disease nondiabetic origin: possibility of statin therapy].
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Pressure; Cardiotonic Agents; Disease Progression; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Heptanoic Acids; Humans; Lipid Metabolism; Male; Metabolic Diseases; Middle Aged; Prognosis; Pyrroles; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2014 |
Chlorogenic acid protects against atherosclerosis in ApoE-/- mice and promotes cholesterol efflux from RAW264.7 macrophages.
Topics: Animals; Anticholesteremic Agents; Aorta; Apolipoproteins E; Atherosclerosis; Atorvastatin; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Biological Transport; Caffeic Acids; Cell Line; Chlorogenic Acid; Cholesterol; Cholesterol, LDL; Coumaric Acids; Diet, High-Fat; Gallic Acid; Gene Expression; Lipoproteins; Lipoproteins, LDL; Liver X Receptors; Macrophages; Mice; Mice, Knockout; Orphan Nuclear Receptors; Plaque, Atherosclerotic; PPAR gamma; Triglycerides; Vasodilation | 2014 |
Evaluation of the effect of andrographolide on atherosclerotic rabbits induced by Porphyromonas gingivalis.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Bacteroidaceae Infections; C-Reactive Protein; Cytokines; Diterpenes; Female; Heptanoic Acids; Lipids; Male; Muscle, Smooth; Porphyromonas gingivalis; Pyrroles; Rabbits; Tunica Intima | 2014 |
The low-dose atorvastatin and valsartan combination effectively protects the arterial wall from atherogenic diet-induced impairment in the guinea pig.
Topics: Animals; Aorta, Abdominal; Aorta, Thoracic; Atherosclerosis; Atorvastatin; Diet, Atherogenic; Drug Therapy, Combination; Female; Guinea Pigs; Heptanoic Acids; Interleukin-1beta; Male; Nitric Oxide Synthase Type III; Plaque, Atherosclerotic; Protective Agents; Pyrroles; Tetrazoles; Valine; Valsartan | 2014 |
Atorvastatin inhibits CD68 expression in aortic root through a GRP78-involved pathway.
Topics: Animals; Anticholesteremic Agents; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Aorta; Atherosclerosis; Atorvastatin; Endoplasmic Reticulum Chaperone BiP; Glucose; Heat-Shock Proteins; Heptanoic Acids; Macrophages; Male; Mesocricetus; Pyrroles; Signal Transduction; Trichothecenes | 2014 |
Effect of atorvastatin on the expression of gamma-glutamyl transferase in aortic atherosclerotic plaques of apolipoprotein E-knockout mice.
Topics: Animals; Aorta; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cholesterol, Dietary; Diet, High-Fat; Disease Models, Animal; Down-Regulation; gamma-Glutamyltransferase; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Intercellular Adhesion Molecule-1; Male; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Pyrroles; Time Factors; Vascular Cell Adhesion Molecule-1 | 2014 |
Synergistic effects of atorvastatin and rosiglitazone on endothelium protection in rats with dyslipidemia.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cytoprotection; Drug Evaluation, Preclinical; Drug Synergism; Dyslipidemias; Endothelium, Vascular; Heptanoic Acids; Male; Myocardium; Oxidative Stress; Pyrroles; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2014 |
Haemostatic risk factors in dyslipidemic rabbits: role of 10-dehydrogingerdione as a new hypolipemic agent.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Coagulation; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Dyslipidemias; Endothelin-1; Endothelium, Vascular; Guaiacol; Nitric Oxide; Plasminogen Activator Inhibitor 1; Rabbits; Treatment Outcome | 2015 |
Small high-density lipoprotein is associated with monocyte subsets in stable coronary artery disease.
Topics: Aged; Atherosclerosis; Atorvastatin; Blood Pressure; Coronary Angiography; Coronary Artery Disease; Cross-Sectional Studies; Female; Fluorobenzenes; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Heptanoic Acids; Humans; Inflammation; Interleukin-10; Lipids; Lipoproteins, HDL; Macrophage Colony-Stimulating Factor; Male; Middle Aged; Monocytes; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2014 |
Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications.
Topics: Angiotensin-Converting Enzyme 2; Animals; Atherosclerosis; Atorvastatin; Disease Models, Animal; Epigenesis, Genetic; Heptanoic Acids; Histones; Male; Peptidyl-Dipeptidase A; Pyrroles; Rabbits; Tissue Distribution; Up-Regulation | 2015 |
The effects of atorvastatin treatment on the mean platelet volume and red cell distribution width in patients with dyslipoproteinemia and comparison with plasma atherogenicity indicators--A pilot study.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoprotein B-100; Atherosclerosis; Atorvastatin; Dyslipidemias; Erythrocyte Indices; Female; Humans; Male; Mean Platelet Volume; Middle Aged; Pilot Projects | 2015 |
Does 10-dehydrogingerdione affect serum albumin and free fatty acid levels as it does on serum ischemia-modified albumin?
Topics: Animals; Atherosclerosis; Atorvastatin; Blood Coagulation; Cholesterol Ester Transfer Proteins; Dyslipidemias; Guaiacol | 2015 |
Establishment of an interleukin-1β-induced inflammation-activated endothelial cell-smooth muscle cell-mononuclear cell co-culture model and evaluation of the anti-inflammatory effects of tanshinone IIA on atherosclerosis.
Topics: Abietanes; Anti-Inflammatory Agents; Atherosclerosis; Atorvastatin; Cell Proliferation; Cells, Cultured; Coculture Techniques; Connexins; Cytokines; Diterpenes; Endothelial Cells; Humans; Inflammation Mediators; Interleukin-1beta; Lipoproteins, LDL; Models, Biological; Myocytes, Smooth Muscle; NF-kappa B; Nitric Oxide; PPAR gamma | 2015 |
Identifying Vulnerable Atherosclerotic Plaque in Rabbits Using DMSA-USPIO Enhanced Magnetic Resonance Imaging to Investigate the Effect of Atorvastatin.
Topics: Animals; Anticholesteremic Agents; Aorta, Abdominal; Atherosclerosis; Atorvastatin; CD40 Ligand; Cholesterol; Contrast Media; Dextrans; Diet, High-Fat; Disease Models, Animal; Gene Expression; Hypercholesterolemia; Magnetic Resonance Imaging; Magnetite Nanoparticles; Male; Matrix Metalloproteinase 9; Plaque, Atherosclerotic; Rabbits; Succimer; Transgenes; Tumor Suppressor Protein p53 | 2015 |
Atorvastatin Attenuates Bone Loss and Aortic Valve Atheroma in LDLR Mice.
Topics: Animals; Anticholesteremic Agents; Aortic Valve; Aortic Valve Stenosis; Atherosclerosis; Atorvastatin; Calcinosis; Cholesterol, Dietary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Macrophages; Mice; Osteogenesis; Osteoporosis; Plaque, Atherosclerotic; X-Ray Microtomography | 2015 |
Atorvastatin Improves Inflammatory Response in Atherosclerosis by Upregulating the Expression of GARP.
Topics: Animals; Apolipoproteins E; Apoptosis; Atherosclerosis; Atorvastatin; Blotting, Western; Cells, Cultured; Flow Cytometry; Immunohistochemistry; Male; Membrane Proteins; Mice; T-Lymphocytes, Regulatory | 2015 |
Increased IL-37 in Atherosclerotic Disease could be Suppressed by Atorvastatin Therapy.
Topics: Animals; Atherosclerosis; Atorvastatin; Foam Cells; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1; Male; Plaque, Atherosclerotic; Rabbits; RNA, Messenger; Smad3 Protein | 2015 |
Effect of diet/atorvastatin on atherosclerotic lesions associated to nonalcoholic fatty liver disease in chickens.
Topics: Animals; Arteries; Atherosclerosis; Atorvastatin; Chickens; Diet; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Non-alcoholic Fatty Liver Disease | 2015 |
Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits.
Topics: Animals; Aorta; Atherosclerosis; Atorvastatin; Biomarkers; Cilostazol; Drug Therapy, Combination; Hypercholesterolemia; Inflammation; Lipids; Male; Oxidation-Reduction; Oxidative Stress; Probucol; Rabbits; Tetrazoles | 2015 |
Should everyone ageing with HIV take a statin?
Topics: Amino Acids; Atherosclerosis; Atorvastatin; Coronary Vessels; Female; HIV Infections; Humans; Male | 2015 |
Ameliorative effect of statin therapy on oxidative damage in heart tissue of hypercholesterolemic rabbits.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Aryldialkylphosphatase; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Diet; Heart; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Malondialdehyde; Nitric Oxide; Oxidation-Reduction; Oxidative Stress; Rabbits; Superoxide Dismutase | 2015 |
A Translational Model for Diet-related Atherosclerosis: Effect of Statins on Hypercholesterolemia and Atherosclerosis in a Minipig.
Topics: Animals; Animals, Genetically Modified; Aorta; Atherosclerosis; Atorvastatin; Diet, High-Fat; Disease Models, Animal; Femoral Artery; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Receptors, LDL; Swine; Swine, Miniature; Translational Research, Biomedical | 2016 |
Synergistic effect of atorvastatin and Cyanidin-3-glucoside on angiotensin II-induced inflammation in vascular smooth muscle cells.
Topics: Angiotensin II; Anthocyanins; Anti-Inflammatory Agents; Atherosclerosis; Atorvastatin; Cell Proliferation; Cells, Cultured; Drug Evaluation, Preclinical; Drug Synergism; Enzyme Induction; Glucosides; Humans; Intercellular Adhesion Molecule-1; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; NF-kappa B; Nitric Oxide Synthase Type II; Oxidation-Reduction; Oxidative Stress; Reactive Oxygen Species; Signal Transduction; Vascular Cell Adhesion Molecule-1; Vasculitis | 2016 |
Regression of Some High-risk Features of Age-related Macular Degeneration (AMD) in Patients Receiving Intensive Statin Treatment.
Topics: Aged; Atherosclerosis; Atorvastatin; Female; Humans; Macular Degeneration; Male; Middle Aged; Pregnancy; Prospective Studies; Retinal Detachment; Retinal Drusen; Retinal Pigment Epithelium; Risk Factors; Tomography, Optical Coherence; Visual Acuity | 2016 |
Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin.
Topics: Animals; Aorta; Atherosclerosis; Atorvastatin; Cholesterol; Cholesterol, LDL; E-Selectin; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Mice; Mice, Knockout, ApoE; Oligonucleotide Array Sequence Analysis; Serum Amyloid A Protein; Treatment Outcome; Vascular Cell Adhesion Molecule-1 | 2016 |
A non-hypocholesterolemic atorvastatin treatment improves vessel elasticity by acting on elastin composition in WHHL rabbits.
Topics: Aging; Animals; Aorta; Arteries; Atherosclerosis; Atorvastatin; Blood Pressure; Collagen; Disease Models, Animal; Elastic Modulus; Elastin; Heart Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pulse Wave Analysis; Rabbits; Stress, Mechanical; Tensile Strength | 2016 |
The role of atorvastatin on the restenosis process post-PTA in a diabetic rabbit model.
Topics: Angioplasty, Balloon; Animals; Atherosclerosis; Atorvastatin; Cell Movement; Cell Proliferation; Constriction, Pathologic; Diabetes Mellitus, Experimental; Disease Models, Animal; Iliac Artery; Male; Myocytes, Smooth Muscle; Neointima; Rabbits; Recurrence; Time Factors; Vascular Patency; Vascular System Injuries | 2016 |
Atorvastatin attenuates p‑cresyl sulfate‑induced atherogenesis and plaque instability in ApoE knockout mice.
Topics: Animals; Anticholesteremic Agents; Aorta; Apolipoproteins E; Atherosclerosis; Atorvastatin; Collagen; Cresols; Intercellular Adhesion Molecule-1; Male; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Sulfuric Acid Esters; Vascular Cell Adhesion Molecule-1 | 2016 |
Multifunctional Dextran Sulfate-Coated Reconstituted High Density Lipoproteins Target Macrophages and Promote Beneficial Antiatherosclerotic Mechanisms.
Topics: Animals; Atherosclerosis; Atorvastatin; Biological Transport; Cholesterol; Dextran Sulfate; Drug Carriers; Humans; Interleukin-10; Interleukin-6; Intracellular Space; Lactic Acid; Lipoproteins, HDL; Lipoproteins, LDL; Macrophages; Mice; Models, Molecular; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Protein Conformation; RAW 264.7 Cells; Surface Properties; Tumor Necrosis Factor-alpha | 2017 |
Microbiome and metabolome modifying effects of several cardiovascular disease interventions in apo-E
Topics: Acetates; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; beta-Glucans; Butyrates; Cardiovascular Diseases; Carnitine; Cholesterol; Cholesterol, Dietary; Diet, High-Fat; Dietary Supplements; Feces; Gastrointestinal Microbiome; Hemiterpenes; Limosilactobacillus reuteri; Male; Metabolome; Mice; Obesity; Pentanoic Acids; Probiotics | 2017 |
Improvement in erectile function in a rat model of high cholesterol diet-induced atherosclerosis by atorvastatin in a manner that is independent of its lipid-lowering property.
Topics: Animals; Aorta, Abdominal; Atherosclerosis; Atorvastatin; Body Weight; Drug Evaluation, Preclinical; Endothelium, Vascular; Erectile Dysfunction; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Male; Nitric Oxide Synthase Type III; Oxidative Stress; Penis; Rats, Sprague-Dawley; Superoxide Dismutase | 2017 |
Short-term evolution (9 months) of aortic atheroma in patients with or without embolic events: a follow-up transoesophageal echocardiographic study.
Topics: Aged; Analysis of Variance; Anticoagulants; Aorta, Thoracic; Atherosclerosis; Atorvastatin; Confidence Intervals; Echocardiography, Transesophageal; Embolism; Female; Follow-Up Studies; Heptanoic Acids; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Prospective Studies; Pyrroles; Risk Assessment; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atherosclerosis; Atorvastatin; Autoantibodies; Biomarkers; Cholesterol, LDL; Coronary Angiography; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin G; Immunoglobulin M; Lipoprotein(a); Male; Malondialdehyde; Middle Aged; Oxidative Stress; Phospholipids; Pravastatin; Prospective Studies; Pyrroles; Research Design | 2008 |
Anti-atherosclerotic effect of atorvastatin and clopidogrel alone and in combination in rats.
Topics: Animals; Atherosclerosis; Atorvastatin; Clopidogrel; Diet, Atherogenic; Drug Interactions; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Platelet Aggregation Inhibitors; Pyrroles; Rats; Rats, Wistar; Ticlopidine | 2008 |
Regression of Achilles tendon thickness after statin treatment in patients with familial hypercholesterolemia: an ultrasonographic study.
Topics: Achilles Tendon; Adult; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk; Ultrasonography; Xanthomatosis | 2009 |
Essential role of TGF-beta/Smad pathway on statin dependent vascular smooth muscle cell regulation.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins E; Apoptosis; Atherosclerosis; Atorvastatin; Cells, Cultured; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Knockout; Models, Biological; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pyrroles; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction; Smad Proteins; Transforming Growth Factor beta | 2008 |
Anti-atherogenic effects of montelukast associated with reduced MCP-1 expression in a rabbit carotid balloon injury model.
Topics: Acetates; Animals; Atherosclerosis; Atorvastatin; Carotid Arteries; Catheterization; Chemokine CCL2; Cyclopropanes; Diet, Atherogenic; Disease Progression; Heptanoic Acids; Immunohistochemistry; Leukotriene Antagonists; Lipids; Male; Pyrroles; Quinolines; Rabbits; Random Allocation; Sulfides | 2009 |
Anti-atherogenic effect of statins: role of nitric oxide, peroxynitrite and haem oxygenase-1.
Topics: Animals; Aorta; Arginine; Atherosclerosis; Atorvastatin; Disease Models, Animal; Endothelium, Vascular; Enzyme Inhibitors; Heme Oxygenase-1; Hemin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Male; Malondialdehyde; Metalloporphyrins; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Peroxynitrous Acid; Protoporphyrins; Pyrroles; Rabbits; Simvastatin; Time Factors | 2009 |
Up-regulating PPAR-γ expression and NO concentration, and down-regulating PAI-1 concentration in a rabbit atherosclerotic model: the possible antiatherogenic and antithrombotic effects of atorvastatin.
Topics: Animals; Atherosclerosis; Atorvastatin; Disease Models, Animal; Down-Regulation; Fibrinolytic Agents; Heptanoic Acids; Male; Nitric Oxide; Plasminogen Activator Inhibitor 1; PPAR gamma; Pyrroles; Rabbits; Up-Regulation | 2010 |
Theranostic strategy against plaque angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Atherosclerosis; Atorvastatin; Carbocyanines; Cyclohexanes; Drug Carriers; Drug Synergism; Drug Therapy, Combination; Fatty Acids, Unsaturated; Heptanoic Acids; Heterocyclic Compounds, 1-Ring; Humans; Integrin alphaVbeta3; Magnetic Resonance Imaging; Nanoparticles; Neovascularization, Pathologic; Pyrroles; Sesquiterpenes; Time Factors | 2008 |
Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis.
Topics: Angiogenesis Inhibitors; Animals; Aorta, Thoracic; Atherosclerosis; Atorvastatin; Carbocyanines; Cyclohexanes; Disease Models, Animal; Drug Carriers; Drug Synergism; Drug Therapy, Combination; Fatty Acids, Unsaturated; Heptanoic Acids; Heterocyclic Compounds, 1-Ring; Integrin alphaVbeta3; Liver; Magnetic Resonance Imaging; Nanoparticles; Neovascularization, Pathologic; Pyrroles; Rabbits; Sesquiterpenes; Time Factors | 2008 |
Statins normalize vascular lysyl oxidase down-regulation induced by proatherogenic risk factors.
Topics: Animals; Atherosclerosis; Atorvastatin; Capillary Permeability; Cattle; Cells, Cultured; Disease Models, Animal; Diterpenes; Dose-Response Relationship, Drug; Down-Regulation; Endothelial Cells; Farnesol; Female; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Protein Kinase C; Protein Kinase Inhibitors; Protein-Lysine 6-Oxidase; Pyrroles; rho-Associated Kinases; rhoA GTP-Binding Protein; Risk Factors; RNA, Messenger; Simvastatin; Swine; Transfection; Tumor Necrosis Factor-alpha | 2009 |
Atorvastatin attenuates TLR4-mediated NF-kappaB activation in a MyD88-dependent pathway.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; B-Lymphocytes; Cell Line; Dendritic Cells; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Lymphocyte Antigen 96; Macrophages; Mice; Myeloid Differentiation Factor 88; NF-kappa B; Pyrroles; Toll-Like Receptor 4; Transfection | 2009 |
Atorvastatin Increases Endoglin, SMAD2, Phosphorylated SMAD2/3 and eNOS Expression in ApoE/LDLR Double Knockout Mice.
Topics: Animals; Anticholesteremic Agents; Aorta; Apolipoproteins E; Atherosclerosis; Atorvastatin; Blotting, Western; Endoglin; Endothelium, Vascular; Female; Heptanoic Acids; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Mice; Mice, Knockout; Nitric Oxide Synthase Type III; Phosphorylation; Pyrroles; Receptors, LDL; Smad2 Protein; Smad3 Protein | 2009 |
Effects of atorvastatin on circulating CD34+/CD133+/ CD45- progenitor cells and indices of angiogenesis (vascular endothelial growth factor and the angiopoietins 1 and 2) in atherosclerotic vascular disease and diabetes mellitus.
Topics: Aged; Angiopoietin-1; Angiopoietin-2; Antigens, CD; Antigens, CD34; Atherosclerosis; Atorvastatin; Diabetes Mellitus; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocyte Common Antigens; Male; Middle Aged; Neovascularization, Pathologic; Prospective Studies; Pyrroles; Stem Cells; Vascular Endothelial Growth Factor A | 2010 |
Angiotensin type 1 receptor expression and interleukin-8 production in polymorphonuclear leukocytes of patients with peripheral arterial disease.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins A; Apolipoproteins B; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Case-Control Studies; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Endarterectomy; Female; Femoral Artery; Gene Expression; Heptanoic Acids; Humans; Interleukin-8; Male; Middle Aged; N-Formylmethionine Leucyl-Phenylalanine; Neutrophils; Peripheral Vascular Diseases; Pyrroles; Receptor, Angiotensin, Type 1; Triglycerides | 2009 |
FDG-PET can distinguish inflamed from non-inflamed plaque in an animal model of atherosclerosis.
Topics: Animals; Aorta; Atherosclerosis; Atorvastatin; Catheterization; Cholesterol, Dietary; Diagnosis, Differential; Disease Models, Animal; Fluorodeoxyglucose F18; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Macrophages; Male; Positron-Emission Tomography; Predictive Value of Tests; Pyrroles; Rabbits; Radiopharmaceuticals | 2010 |
18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Binding, Competitive; Cells, Cultured; Contrast Media; Disease Models, Animal; Endothelium, Vascular; Feasibility Studies; Fluorodeoxyglucose F18; Graft Rejection; Half-Life; Heart Transplantation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Iopamidol; Ligands; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Peptides; Positron-Emission Tomography; Predictive Value of Tests; Pyrroles; Radiopharmaceuticals; Reproducibility of Results; RNA, Messenger; Tissue Distribution; Tomography, X-Ray Computed; Vascular Cell Adhesion Molecule-1 | 2009 |
Three-dimensional carotid ultrasound segmentation variability dependence on signal difference and boundary orientation.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Biometry; Carotid Arteries; Carotid Stenosis; Female; Heptanoic Acids; Humans; Imaging, Three-Dimensional; Male; Middle Aged; Pattern Recognition, Automated; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Surface Properties; Ultrasonography | 2010 |
Montelukast inhibits matrix metalloproteinases expression in atherosclerotic rabbits.
Topics: Acetates; Animals; Atherosclerosis; Atorvastatin; Cyclopropanes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukotriene Antagonists; Lipids; Macrophages; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Myocytes, Smooth Muscle; Pyrroles; Quinolines; Rabbits; Random Allocation; Reverse Transcriptase Polymerase Chain Reaction; Sulfides | 2009 |
Effects of clopidogrel on vascular proliferation and apoptosis in an atherosclerotic rabbit model.
Topics: Animals; Apoptosis; Atherosclerosis; Atorvastatin; C-Reactive Protein; Catheterization; Clopidogrel; Endothelium, Vascular; Heptanoic Acids; Inflammation; Male; Platelet-Derived Growth Factor; Pyrroles; Rabbits; Random Allocation; Ticlopidine; Tunica Intima | 2010 |
Texture analysis of carotid artery atherosclerosis from three-dimensional ultrasound images.
Topics: Aged; Algorithms; Atherosclerosis; Atorvastatin; Carotid Arteries; Female; Heptanoic Acids; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Male; Middle Aged; Models, Statistical; Pyrroles; Reproducibility of Results; Ultrasonography | 2010 |
[Case of branch atheromatous disease presenting capsular warning syndrome].
Topics: Anticoagulants; Aspirin; Atherosclerosis; Atorvastatin; Dextrans; Diffusion Magnetic Resonance Imaging; Drug Therapy, Combination; Heptanoic Acids; Humans; Infusions, Intravenous; Ischemic Attack, Transient; Magnetic Resonance Angiography; Male; Middle Aged; Pyrroles; Recurrence; Syndrome; Thrombolytic Therapy; Tissue Plasminogen Activator | 2010 |
Celecoxib combined with atorvastatin prevents progression of atherosclerosis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Celecoxib; Chemokine CCL2; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Progression; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Pyrazoles; Pyrroles; Sulfonamides; Vascular Cell Adhesion Molecule-1 | 2010 |
In vitro modulation of peroxisome proliferator-activated receptor-gamma and its genes by C-reactive protein. Role of atorvastatin.
Topics: Atherosclerosis; Atorvastatin; Base Sequence; C-Reactive Protein; Cell Line; Cell Proliferation; Cell Survival; DNA Primers; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver X Receptors; Matrix Metalloproteinase 9; Orphan Nuclear Receptors; PPAR gamma; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2010 |
Cholesteryl ester transfer protein antagonism by drugs--a poor choice.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Polymorphism, Genetic; Pyrroles; Quinolines; Risk | 2010 |
Development of a population pharmacokinetic model for atorvastatin acid and its lactone metabolite.
Topics: Adult; Aged; Area Under Curve; Atherosclerosis; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Male; Middle Aged; Models, Biological; Pyrroles | 2010 |
Up-regulation of hepatic low-density lipoprotein receptor-related protein 1: a possible novel mechanism of antiatherogenic activity of hydroxymethylglutaryl-coenzyme A reductase inhibitor Atorvastatin and hepatic LRP1 expression.
Topics: Animals; Antigens, CD; Atherosclerosis; Atorvastatin; Dietary Fats; Hep G2 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Liver; Low Density Lipoprotein Receptor-Related Protein-1; Pyrroles; Rats; Rats, Long-Evans; Rats, Sprague-Dawley; RNA, Small Interfering; Sterol Regulatory Element Binding Protein 2; Sterol Regulatory Element Binding Proteins; Up-Regulation | 2011 |
Effects of immunomodulatory drugs on plasma inflammatory markers in a rabbit model of atherosclerosis.
Topics: Animals; Atherosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, LDL; Cyclosporine; Heptanoic Acids; Immunologic Factors; Inflammation; Interferon-gamma; Interleukin-6; Male; Plasma; Pyrroles; Rabbits; Tacrolimus; Triglycerides | 2011 |
Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE deficient mice independent of plasma cholesterol levels.
Topics: Angiogenesis Inhibitors; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cell Line; Cell Proliferation; Cholesterol; Connective Tissue; Disease Models, Animal; Endothelial Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Knockout; Microvessels; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Pyrroles; Time Factors | 2011 |
[Atorvastatin and oxidized low density lipoprotein antibody. Relationship to age].
Topics: Adult; Age Factors; Aged; Atherosclerosis; Atorvastatin; Autoantibodies; Autoantigens; Blood Glucose; C-Reactive Protein; Creatinine; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipid Peroxidation; Lipids; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Risk Factors; Waist Circumference | 2011 |
Simultaneous intake of oat bran and atorvastatin reduces their efficacy to lower lipid levels and atherosclerosis in LDLr-/- mice.
Topics: Adipose Tissue; Animals; Anticholesteremic Agents; Aorta; Atherosclerosis; Atorvastatin; Avena; beta-Glucans; Blood; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Dietary Fiber; Eating; Female; Heptanoic Acids; Intestinal Absorption; Lipids; Liver; Mice; Mice, Inbred Strains; Mice, Knockout; Plaque, Atherosclerotic; Pyrroles; Receptors, LDL; Treatment Outcome; Triglycerides | 2011 |
Endoglin as a possible marker of atorvastatin treatment benefit in atherosclerosis.
Topics: Activin Receptors, Type I; Activin Receptors, Type II; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Biomarkers, Pharmacological; Blood; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Endoglin; Female; Heptanoic Acids; Intracellular Signaling Peptides and Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Phosphorylation; Plaque, Atherosclerotic; Pyrroles; Receptors, LDL; Sinus of Valsalva; Smad1 Protein; Vascular Endothelial Growth Factor A | 2011 |
Statins exert differential effects on angiotensin II-induced atherosclerosis, but no benefit for abdominal aortic aneurysms.
Topics: Angiotensin II; Animal Feed; Animals; Anti-Inflammatory Agents; Aorta; Aortic Aneurysm, Abdominal; Apolipoproteins E; Atherosclerosis; Atorvastatin; Blood Pressure; Fluorobenzenes; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Mice; Mice, Inbred C57BL; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2011 |
Combination therapy of candesartan with statin inhibits progression of atherosclerosis more than statin alone in patients with coronary artery disease.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Benzimidazoles; Biomarkers; Biphenyl Compounds; C-Reactive Protein; Cholesterol; Coronary Artery Disease; Dinoprost; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Longitudinal Studies; Male; Matrix Metalloproteinase 9; Middle Aged; Pyrroles; Tetrazoles; Tomography, X-Ray Computed | 2011 |
Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation.
Topics: Animals; Antioxidants; Aorta; Aortic Diseases; Aryldialkylphosphatase; Atherosclerosis; Atorvastatin; Catalase; Disease Models, Animal; Erythrocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Peroxidation; Lipoproteins, LDL; Male; Oxidation-Reduction; Plaque, Atherosclerotic; Pyrroles; Rabbits; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances; Time Factors | 2011 |
Therapy and clinical trials: aggressive statin therapy versus combined and emerging approaches.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Clinical Trials as Topic; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Atorvastatin inhibits homocysteine-induced endoplasmic reticulum stress through activation of AMP-activated protein kinase.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blotting, Western; Dose-Response Relationship, Drug; Endoplasmic Reticulum Stress; Heptanoic Acids; Homocysteine; Human Umbilical Vein Endothelial Cells; Humans; Lipids; Mice; Polymerase Chain Reaction; Pyrroles; Ribonucleotides; Time Factors | 2012 |
Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(-/-) mice.
Topics: Animals; Atherosclerosis; Atorvastatin; CD4-Positive T-Lymphocytes; Cholesterol; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Cellular; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Mice; Mice, Inbred C57BL; Mycophenolic Acid; Pyrroles | 2012 |
Anti-inflammatory and anti-thrombotic intervention strategies using atorvastatin, clopidogrel and knock-down of CD40L do not modify radiation-induced atherosclerosis in ApoE null mice.
Topics: Animals; Anti-Inflammatory Agents; Apolipoproteins E; Atherosclerosis; Atorvastatin; Carotid Arteries; CD40 Antigens; Clopidogrel; Disease Models, Animal; Heptanoic Acids; Immunohistochemistry; Mice; Mice, Inbred C57BL; Mice, Knockout; Platelet Aggregation Inhibitors; Pyrroles; Radiation Dosage; Radiation Injuries, Experimental; Random Allocation; Reference Values; Statistics, Nonparametric; Ticlopidine | 2011 |
Should children and adolescents with systemic lupus erythematosus be given statin therapy to prevent early atherosclerosis?
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Female; Heptanoic Acids; Humans; Lupus Erythematosus, Systemic; Male; Pyrroles | 2012 |
Activation of TGF-β receptors and Smad proteins by atorvastatin is related to reduced atherogenesis in ApoE/LDLR double knockout mice.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins E; Atherosclerosis; Atorvastatin; Blotting, Western; Cholesterol; Endoglin; Female; Heptanoic Acids; Immunoenzyme Techniques; Intracellular Signaling Peptides and Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide Synthase Type III; Protein Serine-Threonine Kinases; Pyrroles; Receptor, Transforming Growth Factor-beta Type I; Receptors, LDL; Receptors, Transforming Growth Factor beta; Smad1 Protein; Smad2 Protein; Vascular Endothelial Growth Factor A | 2012 |
Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin.
Topics: Amides; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Female; Fumarates; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Transgenic; Pyrroles | 2012 |
Does the combination of a renin inhibitor with a statin have potential for improved inhibition of atherosclerosis?
Topics: Amides; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Female; Fumarates; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2012 |
Statins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophages.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cell Movement; Cholesterol; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Mice; Mice, Transgenic; Models, Biological; Monocytes; Promoter Regions, Genetic; Pyrroles; Receptors, CCR7; Response Elements; Sterol Regulatory Element Binding Proteins; Sterols | 2011 |
Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acute Coronary Syndrome; Aged; Atherosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Lipoproteins; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Ischemia; Oxidation-Reduction; Phospholipases A2, Secretory; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk; Risk Factors; Survival Analysis | 2012 |
Nitric oxide enhances the anti-inflammatory and anti-atherogenic activity of atorvastatin in a mouse model of accelerated atherosclerosis.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Disease Models, Animal; Heptanoic Acids; Inflammation; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide; Pyrroles; Receptors, LDL | 2012 |
The effect of herb-partition moxibustion on Toll-like receptor 4 in rabbit aorta during atherosclerosis.
Topics: Animals; Anticholesteremic Agents; Antigens; Aorta; Atherosclerosis; Atorvastatin; Diet, High-Fat; Disease Models, Animal; Heptanoic Acids; Magnoliopsida; Moxibustion; Plant Preparations; Polymerase Chain Reaction; Pyrroles; Rabbits; Random Allocation; RNA, Messenger; Toll-Like Receptor 4 | 2012 |
Nitric oxide-donating statins: a new concept to boost the lipid-independent effects.
Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Atorvastatin; Heptanoic Acids; Nitric Oxide; Pyrroles | 2012 |
Effects of atorvastatin on expression of ICAM-1 in atherosclerotic rabbits.
Topics: Animals; Atherosclerosis; Atorvastatin; Disease Models, Animal; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Intercellular Adhesion Molecule-1; Male; Pyrroles; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2013 |
Effectiveness of lipid-lowering therapy with statins for secondary prevention of atherosclerosis--guidelines vs. reality.
Topics: Atherosclerosis; Atorvastatin; Cholesterol, LDL; Decision Making; Diet, Fat-Restricted; Diet, Reducing; Dose-Response Relationship, Drug; Female; Health Surveys; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Male; Middle Aged; Patient Compliance; Poland; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrroles; Rural Population; Secondary Prevention; Simvastatin; Urban Population | 2012 |
Effect of raloxifene and atorvastatin in atherosclerotic process in ovariectomized rats.
Topics: Animals; Aorta, Thoracic; Atherosclerosis; Atorvastatin; Chemokine CCL2; Endothelium, Vascular; Estrogen Antagonists; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Ovariectomy; Pyrroles; Raloxifene Hydrochloride; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha | 2013 |
[Specific features of hypolipidemic therapy in patients with abdominal ischemic disease].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Aorta, Abdominal; Atherosclerosis; Atorvastatin; Cholagogues and Choleretics; Drug Therapy, Combination; Fatty Liver; Female; Heptanoic Acids; Humans; Ischemia; Male; Middle Aged; Pyrroles; Ursodeoxycholic Acid; Young Adult | 2012 |
Genetic variants in genes related to lipid metabolism and atherosclerosis, dyslipidemia and atorvastatin response.
Topics: Atherosclerosis; Atorvastatin; Dyslipidemias; Female; Genotype; Heptanoic Acids; Humans; Lipid Metabolism; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles; Treatment Outcome | 2013 |
Use of secondary preventive medications in patients with atherosclerotic disease in urban China: a cross-sectional study of 16, 860 patients.
Topics: Aged; Aged, 80 and over; Atherosclerosis; Atorvastatin; Cerebrovascular Disorders; Coronary Artery Disease; Cross-Sectional Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Peripheral Vascular Diseases; Pyrroles; Secondary Prevention; Simvastatin | 2012 |
Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice.
Topics: Animals; Atherosclerosis; Atorvastatin; Biomarkers; Cholesterol, Dietary; Cholesterol, LDL; Drug Synergism; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Mice; Mice, Transgenic; Oxidative Stress; Pyrroles; Resveratrol; Stilbenes | 2013 |
Nitric oxide-donating atorvastatin attenuates neutrophil recruitment during vascular inflammation independent of changes in plasma cholesterol.
Topics: Acute Disease; Animals; Atherosclerosis; Atorvastatin; Carotid Arteries; Cell Survival; Chemotaxis, Leukocyte; Cholesterol; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Interleukin-8; Male; Molecular Structure; Monocytes; Neutrophil Infiltration; Neutrophils; Nitric Oxide Donors; Pyrroles; Rabbits | 2013 |
[Atorvastatin: lipid lowering activity, pleiotropic properties and efficacy in prevention of atherosclerosis and coronary heart disease].
Topics: Atherosclerosis; Atorvastatin; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2004 |
Margarine phytosterols decrease the secretion of atherogenic lipoproteins from HepG2 liver and Caco2 intestinal cells.
Topics: Anticholesteremic Agents; Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins B; Atherosclerosis; Atorvastatin; Caco-2 Cells; Carcinoma, Hepatocellular; Cholesterol; Drug Synergism; Enterocytes; Hepatocytes; Heptanoic Acids; Humans; Liver Neoplasms; Margarine; Phytosterols; Pyrroles; Sitosterols; Stigmasterol | 2005 |
Combined effects of HMG-CoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Benzimidazoles; Benzoates; Chemokine CCL2; Disease Models, Animal; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Interleukin-10; Interleukin-6; Macrophages; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Monocytes; Pyrroles; Ramipril; Renin-Angiotensin System; Telmisartan | 2005 |
Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits.
Topics: Animals; Aortic Diseases; Atherosclerosis; Atorvastatin; Cholesterol, Dietary; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Male; Pyrroles; Rabbits | 2005 |
Matrix metalloproteinases in isolated hypercholesterolemia.
Topics: Atherosclerosis; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Matrix Metalloproteinases; Middle Aged; Pyrroles; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinases | 2005 |
Lipid-lowering with atorvastatin improves tissue characteristics of carotid plaque.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Artery Diseases; Carotid Artery, Common; Carotid Artery, Internal; Female; Follow-Up Studies; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Pyrroles; Treatment Outcome; Ultrasonography | 2005 |
Torcetrapib + atorvastatin (Pfizer).
Topics: Animals; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Combinations; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Quinolines | 2005 |
99mTc-interleukin-2 scintigraphy for the in vivo imaging of vulnerable atherosclerotic plaques.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Arteries; Diet, Atherogenic; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-2; Male; Middle Aged; Pyrroles; Radionuclide Imaging; Technetium | 2006 |
A case of familial hypercholesterolemia; secession from LDL-apheresis by the drug treatment with potent statin and resin.
Topics: Achilles Tendon; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Component Removal; Coronary Vessels; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Middle Aged; Pedigree; Pyrroles; Radiography; Xanthomatosis | 2005 |
MDOC and atorvastatin have potential antiinflammatory effects in vascular endothelium of apoE-/- mouse model of atherosclerosis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cellulose, Oxidized; Diet; Disease Models, Animal; Endothelium, Vascular; Heptanoic Acids; Hyperlipidemias; Intercellular Adhesion Molecule-1; Lipoproteins; Male; Mice; Mice, Knockout; Pyrroles; Simvastatin; Triglycerides; Vascular Cell Adhesion Molecule-1 | 2006 |
[Drug combinations: statins and niacin].
Topics: Age Distribution; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Niacin; Pyrroles; Sex Factors; Simvastatin | 2005 |
Atorvastatin reduces the expression of prostaglandin E2 receptors in human carotid atherosclerotic plaques and monocytic cells: potential implications for plaque stabilization.
Topics: Aged; Atherosclerosis; Atorvastatin; Carotid Artery Diseases; Cells, Cultured; Cyclooxygenase 2; Dinoprostone; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracellular Signaling Peptides and Proteins; Intramolecular Oxidoreductases; Male; Matrix Metalloproteinase 1; Mevalonic Acid; Middle Aged; Monocytes; Prostaglandin-E Synthases; Protein Serine-Threonine Kinases; Pyrroles; Receptors, Prostaglandin E; rho GTP-Binding Proteins; rho-Associated Kinases | 2006 |
Anti-atherosclerotic effect of amlodipine, alone and in combination with atorvastatin, in APOE*3-Leiden/hCRP transgenic mice.
Topics: Amlodipine; Animals; Apolipoprotein E3; Apolipoproteins E; Atherosclerosis; Atorvastatin; Blood Pressure; C-Reactive Protein; Cholesterol; Disease Models, Animal; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Mice; Mice, Transgenic; Pyrroles; Serum Amyloid A Protein; von Willebrand Factor | 2006 |
Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism.
Topics: Antioxidants; Apoptosis; Atherosclerosis; Atorvastatin; Cell Membrane; Cholesterol, LDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Lipid Peroxidation; Membrane Lipids; Models, Biological; Oxidative Stress; Pyrroles; X-Ray Diffraction | 2006 |
Atorvastatin reduces plasminogen activator inhibitor-1 expression in adipose tissue of atherosclerotic rabbits.
Topics: Adipose Tissue; Animal Feed; Animals; Atherosclerosis; Atorvastatin; Cholesterol; Gene Expression Regulation; Heptanoic Acids; Male; Mevalonic Acid; Plasminogen Activator Inhibitor 1; Pyrroles; Rabbits; RNA, Messenger; Triglycerides | 2006 |
Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin.
Topics: Atherosclerosis; Atorvastatin; Base Sequence; Cell Movement; Cell Proliferation; Cells, Cultured; Coronary Vessels; DNA, Complementary; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-18; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Muscle, Smooth, Vascular; NF-kappa B; Phosphatidylinositol 3-Kinases; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Pyrroles; Recombinant Proteins; RNA, Messenger; Transcription Factor AP-1 | 2006 |
Atorvastatin prevents hypoxia-induced inhibition of endothelial nitric oxide synthase expression but does not affect heme oxygenase-1 in human microvascular endothelial cells.
Topics: Atherosclerosis; Atorvastatin; Blotting, Western; Cells, Cultured; Endothelium, Vascular; Gene Expression Regulation, Enzymologic; Heme Oxygenase-1; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypoxia; Microcirculation; Nitric Oxide Synthase Type III; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Statin treatment is not associated with consistent alterations in inflammatory status of carotid atherosclerotic plaques: a retrospective study in 378 patients undergoing carotid endarterectomy.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Atherosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Cytokines; Dose-Response Relationship, Drug; Endarterectomy, Carotid; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Inflammation; Macrophages; Peptide Hydrolases; Phenotype; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin | 2006 |
Atorvastatin reduces tissue factor expression in adipose tissue of atherosclerotic rabbits.
Topics: Animals; Atherosclerosis; Atorvastatin; Heptanoic Acids; Male; Pyrroles; Rabbits; Subcutaneous Fat; Thromboplastin | 2007 |
The anti-atherosclerotic effects of lipid lowering with atorvastatin in patients with hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipids; Male; Middle Aged; Pyrroles; Time Factors; Tunica Intima; Tunica Media | 2006 |
Atorvastatin has distinct effects on endothelial markers in different mouse models of atherosclerosis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Biomarkers; Diet, Atherogenic; Endothelium, Vascular; Heptanoic Acids; Intercellular Adhesion Molecule-1; Lipid Metabolism; Lipoproteins; Male; Mice; Mice, Inbred C57BL; Pyrroles; Vascular Cell Adhesion Molecule-1 | 2006 |
Statin treatment, reduced T-cell content of atherosclerotic plaques and cancer.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Heptanoic Acids; Humans; Immunity, Cellular; Neoplasms; Pyrroles; T-Lymphocytes | 2006 |
Effect of clopidogrel on the inflammatory progression of early atherosclerosis in rabbits model.
Topics: Animals; Aspirin; Atherosclerosis; Atorvastatin; Chemokine CCL2; Clopidogrel; Diet, Atherogenic; Disease Models, Animal; Femoral Artery; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Intercellular Adhesion Molecule-1; Male; P-Selectin; Platelet Aggregation Inhibitors; Pyrroles; Rabbits; Ticlopidine; Vascular Cell Adhesion Molecule-1 | 2007 |
Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization.
Topics: Angioplasty, Balloon, Coronary; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Biopsy, Needle; Cells, Cultured; Chemokine CCL19; Chemokine CCL21; Chemokines, CC; Coronary Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Gene Expression Regulation; Heptanoic Acids; Humans; Immunohistochemistry; In Vitro Techniques; Leukocytes, Mononuclear; Mice; Mice, Transgenic; Prognosis; Pyrroles; Receptors, CCR7; Receptors, Chemokine; Reference Values; Risk Factors; RNA, Messenger; Sensitivity and Specificity; Simvastatin; Treatment Outcome | 2007 |
L-arginine plus atorvastatin for prevention of atheroma formation in genetically hypercholesterolaemic rabbits.
Topics: Animals; Arginine; Atherosclerosis; Atorvastatin; Cholesterol; Combined Modality Therapy; Dietary Supplements; Eating; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Nitric Oxide; Pyrroles; Rabbits | 2007 |
[The 2006 American Heart Association selection of the "top ten advances in heart disease and stroke research"].
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; American Heart Association; Anti-Inflammatory Agents; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Brain Ischemia; Child; Coronary Disease; Heart Diseases; Heart Valve Prosthesis; Heart-Assist Devices; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Obesity; Peptidyl-Dipeptidase A; Process Assessment, Health Care; Pyrroles; Stroke; Tissue Engineering; United States | 2007 |
HDL cholesterol and atherosclerosis.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Arteries; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Heptanoic Acids; Humans; Pyrroles; Quinolines; Tunica Intima | 2007 |
Metabolic syndrome with early aortic atherosclerosis in a child.
Topics: Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Atorvastatin; Child; Cholesterol; Cholesterol, HDL; Fish Oils; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Magnetic Resonance Imaging; Male; Metabolic Syndrome; Obesity; Pyrroles; Treatment Outcome; Triglycerides | 2006 |
Effects of toll-like receptor-4 gene polymorphisms on soluble P-selectin and von Willebrand factor levels in hypercholesterolemic patients.
Topics: Adult; Aged; Atherosclerosis; Atorvastatin; Case-Control Studies; Cohort Studies; Cross-Sectional Studies; Female; Gene Frequency; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; P-Selectin; Phenotype; Polymorphism, Genetic; Pyrroles; Risk Factors; Toll-Like Receptor 4; Treatment Outcome; von Willebrand Factor | 2007 |
Dual mode of HMG-CoA reductase inhibition on dendritic cell invasion.
Topics: Antibodies; Atherosclerosis; Atorvastatin; Cell Adhesion; Cell Line; Cell Movement; Cholesterol; Dendritic Cells; Dose-Response Relationship, Drug; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Prenylation; Pyrroles; Vasculitis | 2008 |
[Assessment of hypolipidemic efficacy and safety of various doses of atorvastatin].
Topics: Administration, Oral; Adult; Aged; Atherosclerosis; Atorvastatin; Biomarkers; Cholesterol, HDL; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2007 |
Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis.
Topics: Acetamides; Acetates; Animals; Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Atorvastatin; Catheterization; Cholesterol; Disease Progression; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Magnetic Resonance Imaging; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Pyrroles; Rabbits; Random Allocation; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids | 2007 |
Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin.
Topics: Animals; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Drug Synergism; Heptanoic Acids; Inflammation; Mice; Mice, Inbred Strains; Pyrroles; Quinolines | 2008 |
Short term effects of atorvastatin on endothelial functions and oxidized LDL levels in patients with type 2 diabetes.
Topics: Atherosclerosis; Atorvastatin; Biomarkers; Brachial Artery; Carotid Arteries; Cholesterol, LDL; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Inflammation; Lipids; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Tunica Intima | 2008 |